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Abstract
This translational research piece involved collaborating with a local community
mental health agency to examine knowledge, skills, attitudes, practices, and outcomes
for panic disorder treatments. The project included designing and administering an
online survey to client care personnel including psychologists, counselors, social
workers, nurses, and psychiatrists. Additionally, a database review was utilized to
obtain information about treatment modalities, duration, and outcomes. Survey results
were analyzed using goodness of fit statistics to show differences between attitudes of
participants by discipline regarding the safety and effectiveness of panic disorder
treatments. The database analysis of pre and post GAF scores revealed comparable
outcomes for therapy alone and therapy and medication treatment groups.
Additionally, clients receiving therapy and medication for panic disorder were shown
to have had significantly longer treatment duration on average than those in therapy
only. These findings were discussed in terms of existing literature on panic disorder
treatment and organizational change to make recommendations for the participating
agency and others like it.
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Diffusion of Innovative Panic Disorder Treatment Strategies in a Community
Mental Health Agency
Summary of Problem
The following dissertation has been developed in response to obstacles
encountered in implementing standardized panic disorder treatment protocols in a large
metropolitan community mental health agency. A large number of studies have been
conducted that appear to support the efficacy of Cognitive-Behavioral Therapy (CBT) for
managing the symptoms of panic disorder and decreasing dependency on psychotropic
medications for the treatment of anxiety (Gould, Otto, & Pollack, 1995; Otto et al., 1993;
Spiegel, Bruce, Gregg, & Nuzzarello, 1994). However, there seems to be a dearth of
translational research that could aid community mental health agencies in understanding
the procedures of successfully navigating the process of implementing an innovative
program for addressing the need for a balanced practice to treatment of anxiety disorders
in a real practice setting.
Panic disorder, an anxiety diagnosis that is characterized by recurrent unexpected
panic attacks, is one of the most commonly treated mental health issues (American
Psychiatric Association, 2000; Kessler, Berglund, Demler, Jin, & Walters, 2005; World
Health Organization, 1998). Although community population samples have been found
to have lifetime prevalence rates of between one and two percent for this diagnosis,
clinical populations report a much higher rate of about 10 percent lifetime prevalence.
Additionally, Kessler and colleagues’ National Comorbidity Survey Replication (NCS1

R), which reported prevalence findings based on symptom report as opposed to diagnosis,
revealed a higher rate of 4.7 percent lifetime prevalence for the general U.S. population.
Individuals with anxiety disorders frequently exhibit the mental and physiological
reactions associated with fear in response to non-threatening stimuli and situations
(American Psychiatric Association, 2000; World Health Organization, 1998). This is
particularly common for individuals with panic disorder, whose fear of recurrent panic
attacks can lead to restrictive behavioral patterns. These individuals may also develop
symptoms of agoraphobia, a fear of going outside or being among crowds of people, due
to apprehension about being in public settings where they cannot escape or control a
possible panic attack. Consequently, they often develop avoidance strategies that interfere
with social and occupational functioning. The course of panic disorder may be either
constant or episodic, but it is almost always chronic. Therefore, it requires treatment
methods that can deliver sustainable improvement.
Current recommended treatment practices for panic disorder include
pharmacological treatments, behavioral health interventions, or a combination of these
modalities (American Psychiatric Association, 2009; World Health Organization, 1998).
Pharmacological intervention generally includes the use of benzodiazepine, Selective
Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor
(SNRI), or Tricyclic Antidepressant (TCA) prescriptions for the management of panic
attack symptoms. Behavioral healthcare interventions designed for the treatment of panic
disorder include CBT with exposure techniques, Panic Focused Psychodynamic
Psychotherapy (PFPP), and Emotion-Focused Psychotherapy for Panic Disorder
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(EFPPD) (Barlow, 2002; Milrod, Busch, Cooper, & Shapiro, 1997; Milrod et al., 2007;
Shear, Houck, Greeno, & Masters, 2001).
Antidepressant medications such as TCAs (imipramine and clomipramine), SSRIs
(fluoxetine, sertraline, escitalopram, fluvoxamine, and paroxetine), and SNRIs
(venlafaxine) have generally received favorable reviews in clinical trials for the treatment
of panic disorder. A number of studies using a variety of antidepressants have found a
decrease in the rates of panic attacks for participants when compared to those given a
placebo, and these findings appear to be sustained for the duration of the pharmacological
treatment (Hoehn-Saric, McLeod, & Hipsley, 1993; Pollack et al., 2007; Sheikh,
Londborg, Clary, & Fayyad, R. 2000). However, it appears that troublesome side effects
such as those related to sexual dysfunction or weight gain may lead to premature and
abrupt termination of antidepressant treatments (American Psychiatric Association,
2009). Cessation of the antidepressant medication is usually associated with a return of
panic attacks, as well as bothersome discontinuation syndrome symptoms including
gastrointestinal and sleep disturbances in the case of abrupt termination of
pharmacological treatment. Additionally, some research suggests that the use of an
antidepressant medication treatment regimen may lead to an increase in the risk for
suicide and self-harm, and the potential benefits and risks should be evaluated by
considering all of the above factors (Fergusson et al., 2005; Gunnell, Saperia, & Ashby,
2005).
The use of benzodiazepines such as lorazepam (Ativan), clonazepam (Klonopin),
and alprazolam (Xanax) to treat panic disorder appears to be an effective treatment
strategy so long as the client continues to take the medication as prescribed; however,
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discontinuation often leads to relapse and bothersome symptoms of withdrawal in cases
of abrupt cessation (American Psychiatric Association, 2009; Otto, Smits, & Reese,
2006). Several possible problems have been identified related to the use of
benzodiazepines for the treatment of panic disorder. For example, some studies have
shown that benzodiazepines can interfere with the effectiveness of Cognitive-Behavioral
Therapy (Barlow, 2002; Barlow, Gorman, Shear, & Woods, 2000). Specifically, it is
theorized that they superficially attenuate feelings of anxiety and impede clients from
benefiting from exposure based treatment interventions that require that the aversive
reactions be fully experienced in order to truly extinguish that response. Additionally,
other safety concerns that must be considered include the development of physical
dependence and abuse of the medication, increased health and safety risks for elderly
clients, and potentially life-threatening drug or alcohol interactions (American Psychiatric
Association, 2009; Ciraulo, & Nace, 2000; Ciraulo, Sands, & Shader, 1988; French et al.,
2005; Kelly, Darke, & Ross, 2004; Landi et al., 2005)
Behavioral health interventions that have been developed for the treatment of
anxiety include: CBT with exposure techniques, PFPP, and EFPPD (Barlow, 2002;
Milrod, Busch, Cooper, & Shapiro, 1997; Milrod et al., 2007; Shear, Houck, Greeno, &
Masters, 2001). There is little research regarding the efficacy of the supportive form of
counseling utilized in EFPPD. Preliminary findings appear to indicate that it is not as
effective as treatment with pharmacological intervention or CBT treatment strategies in
reducing incidence of panic attacks; however, it appears to be superior to
pharmacological intervention in treatment retention rates (Shear, Houck, Greeno, &
Masters, 2001). PFPP emphasizes the importance of articulation of the relationship
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between the therapist and client, and of understanding the psychological significance of
panic and phobic avoidance (Milrod, Busch, Cooper, & Shapiro, 1997; Milrod et al.,
2007). This method of treatment has demonstrated preliminary comparable efficacy in
the treatment of panic disorder as CBT. CBT treatment of panic disorder is generally
highly structured and usually includes homework that utilizes exposure exercises
involving anxiety provoking stimuli to promote eventual extinction of the panic response
(Barlow, 2002; Barlow, Gorman, Shear, & Woods, 2000). There is significant evidence
that CBT is a more tolerable treatment compared to medications that frequently have
bothersome side effects, and it is more cost-effective when the long-term outcomes such
as strong relapse-prevention effects are considered (American Psychiatric Association,
2009; Barlow, 2002; Barlow, Gorman, Shear, & Woods, 2000).
Despite the above cited evidence for the effectiveness of behavioral treatment
methods, the community mental health agency being examined in this study has reported
an alarming rate of ongoing benzodiazepine prescriptions. This is not necessarily unique
to this agency, which is generally a very strong community mental health center. The
extensive use of benzodiazepine prescriptions nationally in both primary care and in
agency settings has drawn growing attention (Bruce, Vasile, & Goisman, 2003; Smith,
Sketris, Cooke, Gardner, Kisely, & Tett, 2008). This agency is being used in essence as a
“case in point” for the study of current practice and the potential for systemic change in
future practice. Within this treatment agency, possible issues that have been identified
related to the use of benzodiazepines for the treatment of panic disorders include:
interference with behavioral treatment interventions, the development of physical
dependence, the possibility of abuse or sale of the medication, increased health and safety
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risk for elderly clients, potentially life-threatening drug or alcohol interactions, and
wasted clinic resources due to an increased rate of no show/cancellations for therapy
sessions. Therefore, this study has been approved by the agency to elucidate the potential
benefits and dilemmas for implementing innovative best practice standards for the
treatment of panic disorder.
Aim and Purpose
The aim of this study was to collect a profile of knowledge, skills, attitudes, and
current practices within a large community mental health agency in order to examine the
potential options and dilemmas involved in implementing innovative or best practice
guidelines for the treatment of panic disorder. This study utilized methods including
database analysis and record review to formulate an accurate profile of the agency’s
current treatment practices. Additionally, a computerized survey with categorical and
Likert type scaled items was administered to key subgroups that influence client care.
The resulting data were used to provide information regarding the organization’s view of
the potential need for innovative panic disorder treatment practices and possible obstacles
or impediments for implementing changes in treatment standards. Specifically, the
information gathered through these methods was used to formulate answers for three
research questions: (a) To what extent are there differences in current recommendations,
reported practices, and reported knowledge or skills for the treatment of panic disorder at
the community mental health agency being studied? (b) To what extent are there
differences between or within agency cohorts defined by professional affiliation and
educational attainment level as it relates to knowledge, practices, and attitudes regarding
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the treatment of panic disorder? (c) To what extent are treatment outcome variables
related to the type of panic disorder treatment that clients receive?
Successive chapters present a review of the current literature base regarding the
nature of panic disorder with a critical evaluation of current best practice standards for
treatment. The next chapter is devoted to the examination of literature related to
organizational change models with a focus on diffusion of innovations and successful
program implementation in community mental health settings. A chapter that details the
current study includes a description of the institution being studied, the resources utilized
for this research, and the methods of investigation. Finally, qualitative and quantitative
results are discussed in light of organizational change literature and what current results
imply regarding successful treatment strategies for panic disorder in a community mental
health setting.
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Literature Review
Panic Disorder
Panic disorder is a condition characterized by recurrent unexpected panic attacks
that are not due to the direct physiological effects of a substance or a general medical
condition (American Psychiatric Association, 2000; World Health Organization, 1998).
A panic attack is defined as an episode of intense fear or discomfort in the absence of real
danger that is accompanied by physical symptoms. Examples of these somatic symptoms
are tightness or pain in the chest, shortness of breath, pounding or racing heart, sweating,
shaking, nausea, dizziness, or bodily sensations such as tingling, numbness, or hot or cold
flushes. The current diagnostic criteria specify that the individual has had at least two
attacks, and one of those attacks must have resulted in at least a month of persistent
cognitive or behavioral disturbance due to anxiety regarding the experience. Panic
attacks also commonly occur with other anxiety disorders; however, those attacks occur
primarily in response to a feared situation or stimuli. Panic attacks that occur during the
course of panic disorder are described as unexpected, meaning that the individual cannot
readily identify an associated situational trigger. For persons with panic disorder, the
anxiety provoking stimuli are the psychological, physical, and feared consequences of the
attacks themselves.
The psychological experiences of impending doom, loss of control, and going
crazy that accompany panic attacks can lead to persistent and disruptive worry about
experiencing another episode (American Psychiatric Association, 2000; World Health
8

Organization, 1998). This may lead to a catastrophic misinterpretation bias that can
cause individuals with panic disorder to perceive benign bodily sensations such as
increased respirations or heart rate as signs that they are experiencing a heart attack or
some other life threatening ailment (American Psychiatric Association, 2000; Rosmarin,
Bourque, Antony, & McCabe, 2009). Some individuals may become convinced that the
somatic sensations associated with the attacks are signs of an undiagnosed medical
condition and repeatedly seek confirmation of these fears by consulting physicians for
testing. Additionally, the unexpected and intense somatic sensations and cognitive
activation associated with panic attacks may cause individuals to feel as though they are
losing control or going crazy, and many individuals with panic disorder report a fear that
they may vomit, faint, or experience an incontinent episode in public as a result of an
attack. Although at least one study has shown that these events rarely actually occur with
panic attacks, the catastrophic fears of public humiliation can be powerful and
debilitating for individuals with panic disorder (Green, Antony, McCabe, & Watling,
2007).
Behavioral changes associated with the diagnosis of panic disorder are typically
the result of attempts to avoid future attacks and public embarrassment (American
Psychiatric Association, 2000; Batelaan, Graaf, Penninx, Balkom, Vollebergh, &
Beekman, 2009). Unfortunately, individuals that restrict physical exertion, social
contact, and exposure to anxiety provoking situations to reduce the risk of experiencing
another panic attack are also likely to experience disruptions in their occupational,
educational, or familial functioning. The resulting interpersonal relationship difficulties
likely contribute to the increased incidence of comorbidities including major depressive
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disorder, substance abuse, and other anxiety disorders for individuals with panic disorder.
Additionally, if this anxiety leads to avoidance of many situations and severely effects
day-to-day life, panic disorder with agoraphobia may be diagnosed. About one-third to
one-half of persons diagnosed with panic disorder in community samples met criteria for
agoraphobia, but the numbers for clinical sample are believed to be much higher.
Overall, the prognosis for individuals diagnosed with panic disorder appears to
vary greatly depending on factors such as severity and frequency of attacks, educational
level, and presence of comorbid conditions (American Psychiatric Association, 2000;
Batelaan, Graaf, Penninx, Balkom, Vollebergh, & Beekman, 2009). Most longitudinal
research has been conducted in tertiary care settings and indicates that the usual course is
chronic, with either continuous symptom presentation, or discrete periods of remission
and recurrence (American Psychiatric Association, 2000; Goodwin et al., 2005; Pollack
and Smoller, 1995). However, studies that have focused on general population samples
have shown greater variations in the course of the disorder and better overall prognosis
(Batelaan, Graaf, Penninx, Balkom, Vollebergh, & Beekman, 2009; Eaton et al., 1998).
Treatments
Treatment recommendations for panic disorder generally include either the use of
behavioral health interventions such as therapy or pharmacological treatment in the form
of benzodiazepine or antidepressant medications (American Psychiatric Association,
2009; World Health Organization, 1998). Additionally, there is an ongoing debate in the
mental health field about the usefulness of combining pharmacological and behavioral
health strategies in an attempt to capitalize on potential benefits of both treatment
modalities (Barlow et al., 2000; Westra and Stewart, 1998; Uhlenhuth et al., 1999).
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However, there is an apparent lack of consensus or precise guidelines to clarify the
decision making process of choosing the best method of treatment for individuals with
panic disorder (Starcevic, Linden, Uhlenhuth, Kolar, & Latas, 2004; Beamish, Granello,
& Belcastro, 2002; Pollack, 2006). Therefore, the potential benefits and risks of each
treatment option must be considered with respect the individual client’s situation and
needs.
Pharmacological interventions. Medications from several different classes have
been used to stop or reduce the frequency of panic attacks for over 40 years, and current
practice guidelines in pharmacological intervention recommend the use of
antidepressants or benzodiazepine prescriptions for the management of panic disorder
symptoms (American Psychiatric Association, 2009; World Health Organization, 1998).
Specifically, benzodiazepines and antidepressant drugs are the currently most commonly
prescribed anxiolytic agents. Antihypertensive, anticonvulsant, antipsychotic, and older
generation antidepressant medications such as Monoamine Oxidase Inhibitors (MAOIs)
have also been used by some practitioners for the treatment of panic related symptoms;
however, research regarding these medications has shown the potential for serious
medical side effects such as liver failure. The addition of limited favorable research
results and the existence of contradictory findings have caused the American Psychiatric
Association (2009) to not recommend such off-label prescription practices. Therefore,
the focus of this literature review will be limited to the risks and benefits of Selective
Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor
(SNRI), Tricyclic Antidepressant (TCA), and benzodiazepine medications for the
treatment of panic disorder.
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Antidepressants. Antidepressant medications have shown clinical efficacy in the
reduction of number and severity of reported panic attacks, and they have the added
benefit of offering pharmacological coverage for symptoms associated with mood
disorder comorbidities without concerns about dependency or liability for abuse
(American Psychiatric Association, 2009; Pollack, 2006). Three types of antidepressants
are currently recommended as first-line pharmacological treatment options for panic
disorder. Those medication classes are referred to as TCAs, SSRIs, and SNRIs.
The use of TCAs for the management of panic attacks dates back to 1964, when a
trial by Klein (1964) showed that imipramine (Tofranil) was superior to placebo for
reducing panic symptoms. Multiple studies have replicated these findings (Barlow,
Gorman, Shear, & Woods, 2000; Mavissakalian & Perel, 1985; Pollack, Otto, Sachs,
Leon, Shear, Deltito, Keller, & Rosenbaum, 1994; Uhlenhuth, Matuzas, Glass, & Easton,
1998). The results from these studies have shown that after treatment with imipramine
45%-70% of patients were found to be panic free, compared to 15%–50% of those
receiving placebo. Additional findings included that patients with panic disorder who
were treated with imipramine appeared to exhibit less agoraphobic avoidance and
anticipatory anxiety than those receiving placebo.
A number of studies that have utilized placebo-controlled randomized trials
support the acute and long-term efficacy of clomipramine (Anafranil) for the
management of panic disorder symptoms (Bakker, van Dyck, Spinhoven, & van
Balkom,1999; Fahy, O'Rourke, Brophy, Schazmann, & Sciascia, 1992; Johnston, Troyer,
Whitsett, & Dalby, 1995). In fact, research appears to suggest that clomipramine is at
least as effective as imipramine and possibly superior in preventing panic attacks
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(Cassano, Petracca, Perugi, Nisita, Musetti, Mengali, & McNair, 1988; Modigh,
Westberg, & Eriksson,1992). Moreover, most placebo-controlled studies comparing
clomipramine to Selective Serotonin Inhibitors also demonstrate equivalent efficacy in
treating panic disorder; however, there appears to be a less favorable side effect profile
for the TCAs when compared to SSRIs (American Psychiatric Association, 2009;
Bakker, van Dyck, Spinhoven, & van Balkom,1999).
Many side effects of TCAs such as dry mouth, dry nose, blurry vision,
constipation, urinary retention, memory impairment, and increased body temperature are
likely related to their effect on acetylcholine receptors (Physician’s Desk Reference,
2007). Other side effects may include drowsiness, anxiety, anhedonia, confusion,
restlessness, dizziness, changes in appetite and weight, sweating, sexual dysfunction,
weakness, nausea and vomiting, hypotension, tachycardia, and rarely, irregular heart
rhythms. Unfortunately, side effects are relatively common especially during the first few
weeks of treatment (Pollack, 2006). Although dosage of the medication can be titrated up
to a therapeutic level in an attempt to stem these effects, this also has the effect of
delaying treatment benefits. Mavissakalian and Perel (1997) reported that due to these
bothersome side effects they found a higher dropout rate when higher doses of TCAs
were prescribed in their study. However, such abrupt cessation of TCAs is generally
discouraged because it can result in discontinuation syndrome symptoms such as anxiety,
insomnia, headache, nausea, malaise, or motor disturbance (American Psychiatric
Association, 2009; Physician’s Desk Reference, 2007).
Numerous large clinical trials have indicated that SSRIs including sertraline
(Zoloft), fluoxetine (Prozac), paroxetine (Paxil), fluvoxamine (Luvox), citalopram
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(Celexa), and escitalopram (Lexapro) are all effective for the acute and long-term
management of panic disorder (Hoehn-Saric, McLeod, & Hipsley, 1993; Leinonen et al.,
2000; Lepola et al., 1998; Michelson et al., 2001; Michelson et al., 1999; Pohl, Wolkow,
& Clary, 1998; Pollack et al., 2007; Sheikh, Londborg, Clary, & Fayyad 2000; Stahl,
Gergel, & Li, 2003). Although an early meta-analysis by Boyer (1995) suggested that
improvement with SSRIs treatment for panic disorder was significantly greater than for
alprazolam or imipramine, a subsequent meta-analysis incorporating a larger number of
studies showed comparable efficacy for the SSRIs and TCAs (Otto, Tuby, Gould,
McLean, & Pollack, 2001). However, this later study showed mixed results regarding the
question of whether dropout rates were lower in studies in which patients received SSRIs
versus TCAs. Taken together, this research suggests that SSRIs are likely at least as
effective as TCAs and benzodiazepines in the treatment of panic disorder with possibly
fewer associated side effects.
Venlafaxine extended release (Effexor) is the only SNRI that has met the criteria
by the American Psychiatric Association (2009) for recommendation as a treatment of
panic disorder symptoms. Numerous studies have shown it to be as effective as other
antidepressant medications in treating panic disorder Symptoms. For example,
Bradwejn, Ahokas, Stein, Salinas, Emilien, and Whitaker (2005) conducted a large
multicenter study of individuals with panic disorder that demonstrated that a 10-week
course of venlafaxine ER (extended release) resulted in a significantly greater reduction
in frequency of panic attacks than placebo.
Another large multicenter trial included a comparison of the effectiveness of
venlafaxine ER, paroxetine (Paxil), and placebo for the treatment of panic disorder
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without co-occurring depression (Pollack, Lepola, Koponen, Simon, Worthington,
Emilien, Tzanis, Salinas, Whitaker, & Gao, 2007). The results of this study showed both
paroxetine and venlafaxine were significantly more effective than placebo in reducing the
number of panic attacks experienced by participants. Additionally, there were no
significant differences between the venlafaxine ER or paroxetine treatment groups in
terms of efficacy or reported side effects with the exception of somewhat less sedation
reported by the venlafaxine ER than paroxetine treatment group.
Although venlafaxine is the only Serotonin Norepinephrine class medication
currently recommended for the treatment of panic disorder, duloxetine (Cymbalta) is
similar to venlafaxine in its chemical mechanism of action and is currently being
investigated as another potential anxiolytic (American Psychiatric Association, 2009). It
has shown comparable results in preliminary research for its use in the treatment of panic
disorder (Serretti, Chiesa, Calati, Perna, Bellodi, & De Ronchi, 2010). However, further
research is needed to replicate these preliminary findings before it can be deemed a safe
and effective pharmacological treatment option.
The use of serotonergic antidepressants can result in several bothersome side
effects (Physician’s Desk Reference, 2007; Pollack, 2006). These symptoms may
include, but are not limited to, dizziness, headache, apathy, sexual dysfunction, weight
gain, nausea, as well as disturbances in appetite and sleep. Side effects are most
commonly reported in the first few weeks of treatment, and some individuals also report
an exacerbation in jitteriness and anxiety during that period. To counteract these
concerns, dosage is usually started at a lower rate and then titrated up to the therapeutic
level. However, these medications are slow acting to begin with, usually taking between
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6 to 8 weeks to reach effectiveness, and this process may prolong the time it takes for
individuals to start feeling some relief from their panic symptoms. Additionally, if
troublesome side effects or impatience lead to premature termination of antidepressant
treatments, a discontinuation syndrome and return of the panic attack may result
(American Psychiatric Association, 2009). For example, studies show that abrupt
discontinuation of antidepressants can result in withdrawal symptoms such as
incoordination, headache, irritability, and nausea from participants (Shelton, 2006;
Schatzberg, Blier, Delgado, Fava, Haddad, & Shelton, 2006). Additionally, research
suggests that the use of antidepressants may lead to an increased risk for suicide and self
harm is another important factor to consider in recommending a treatment for individuals
with panic disorder (Fergusson et al., 2005; Gunnell, Saperia, & Ashby, 2005).
Another concern regarding the use of antidepressants for the treatment of panic
disorder is that few data suggest an optimum length of treatment following reduction in
symptoms (American Psychiatric Association, 2009). Studies using varying
antidepressant agents have shown that relapse is more common after discontinuation of
the medication when comparing continued medication treatment groups and those tapered
with placebo. Thus, it appears that antidepressants are effective for the management of
panic disorder symptoms only as long as the medication is continued.
Benzodiazepines. Alprazolam (Xanax) has been FDA approved for the treatment
of panic disorder, and it has been studied more extensively than any other
benzodiazepine. In numerous studies alprazolam has been shown to be superior to
placebo in reducing frequency and severity of panic attacks (Dunner, Ishiki, Avery,
Wilson, & Hyde, 1986; Chouinard, Annable, Fontaine, & Solyom, 1982; Tesar et al.,
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1991). Specifically, the studies indicated that about 55% to 75% of participants treated
with alprazolam reported a reduction in panic levels versus about 15% to 50% for the
placebo group participants. In another study alprazolam demonstrated comparable results
in alleviating panic symptoms with lower treatment dropout rates when compared to the
TCA imipramine (Tofranil) (Charney et al., 1986). Additionally, numerous studies
supporting the short-term efficacy of other benzodiazepines such as clonazepam
(Klonopin), diazepam (Valium), and lorazepam (Ativan) have also been published
(Dunner, Ishiki, Avery, Wilson, & Hyde,1986; Charney, & Woods, 1989; Tesar et al.
1991; Schweizer, Pohl, Balon, Fox, Rickels, & Yeragani, 1990). These studies generally
showed a consensus that various benzodiazepine agents demonstrated comparable levels
of symptom reduction rates to those attained by participants treated with alprazolam or
imipramine.
Although consideration of comorbidities is an important step in selecting a
pharmacological agent for the treatment of clients with panic disorder, most of the above
studies excluded participants with a history of diagnosed mood disorders.
Benzodiazepines appear to be ineffective for treatment of mood disorders and may
exacerbate symptoms of depression (Pollack, 2006). However, despite recommendations
from clinical practice guidelines to use antidepressants as first-line pharmacotherapy for
panic disorder, data from the prospective longitudinal Harvard/Brown Anxiety Research
Project showed that most patients treated for panic disorder were still receiving
benzodiazepines (Bruce, Vasile, & Goisman, 2003).
Commonly reported side effects of benzodiazepines include sedation, fatigue,
ataxia, slurred speech, memory impairment, and weakness (Physician’s Desk Reference,
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2007). Research has also suggested that individuals treated with benzodiazepines may be
at risks for increased incidence of motor vehicle accidents and a heightened risk of falls
and fractures for geriatric clients (French, et al., 2005; Kelly, Darke, & Ross, 2004;
Landi, et al., 2005). Additionally, the administration of benzodiazepines for more than 2
to 3 weeks results in physiologic dependence, and withdrawal symptoms such as
insomnia, gastrointestinal problems, tremors, agitation, fearfulness, and muscle spasms
often occur in the case of discontinuation (Physician’s Desk Reference, 2007; Pollack,
2006). Moreover, abrupt cessation of benzodiazepines can result in dangerous side
effects including depression, suicidal behavior, psychosis, seizures, and delirium tremens;
therefore, a physician managed gradual taper is recommended. Due to issues related to
withdrawal symptoms and rebound panic symptoms individuals often experience
difficulty discontinuing benzodiazepines (Klein, Colin, Stolk, & Lenox, 1994; RoyByrne, et al., 2003). Specifically, a study by Fava and colleagues (1995) found that about
30% of participants that received benzodiazepines as part of their treatment regimen were
unable to completely taper off of benzodiazepines use during the treatment period.
Taken together, this literature review yields important information about the
effectiveness and general recommendations regarding pharmacological treatment of panic
disorder. Although antidepressants and benzodiazepines appear to be effective in
reducing panic symptoms, both of these classes of medication are also associated with
specific side effects, safety concerns, and limitations in post treatment response
durability. Specifically, whereas antidepressants offer pharmacological coverage for
symptoms associated with mood disorder comorbidities without concerns about
dependency or liability for abuse, benzodiazepines appear to be ineffective for treatment
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of comorbid mood disorders and may actually exacerbate symptoms of depression
(American Psychiatric Association, 2009; Pollack, 2006). On the other hand,
antidepressants appear to take longer to achieve symptom reduction, have less tolerable
preliminary side effect profiles, and they may cause an initial exacerbation in anxiety
levels. Moreover, cessation of either benzodiazepines or antidepressants has been shown
to result in the development of a discontinuation syndrome that could further complicate
treatment regimens that incorporate the use of these anxiolytic agents. Therefore, it is
recommended that all of these factors be considered when formulating an individualized
treatment plan for clients with panic disorder. Interestingly, despite current clinical
practice guideline recommendations that indicate the use antidepressants as first-line
pharmacotherapy for panic disorder, recent longitudinal research revealed that most
patients treated for panic disorder were still receiving benzodiazepines (Bruce, Vasile, &
Goisman, 2003).
Behavioral health interventions. Most research that has been conducted on the
implementation of behavioral health interventions for the treatment of panic disorder has
focused specifically on Cognitive-Behavioral Therapy (CBT) (American Psychiatric
Association, 2009). Although there is a relative dearth of research with respect to
alternative behavioral health interventions for the treatment of panic disorder, some other
therapeutic approaches that have been investigated include Panic Focused
Psychodynamic Psychotherapy (PFPP) and Emotion-Focused Psychotherapy for Panic
Disorder (EFPPD). The state of research reviewed on PFPP and EFPPD has been
described as preliminary at best; however, a brief examination of the literature regarding

19

the practices and outcomes these two modalities of therapy can provide an informative
point of comparison for considering the use of CBT techniques.
Cognitive-Behavioral Therapy. In terms of CBT, panic disorder is
conceptualized as a maladaptive pattern of thoughts and behaviors that initiate, sustain, or
exacerbate panic symptoms (Sokol, Beck, Greenberg, Wright, & Berchick, 1989). Thus,
the goal is to reduce the fear and avoidance of external and internal cues that have
become associated with panic attacks. This is typically accomplished through a
combination of cognitive restructuring and exposure techniques. Cognitive restructuring
usually focuses on correcting tendencies to catastrophize situations or sensations.
Additionally, behavioral techniques such as interoceptive exposure or inducing of
somatic sensations associated with panic attacks, as well as situational exteroceptive
exposure are used to desensitize clients to panic symptoms. The standard recommended
CBT treatment regimen consists of 12 weekly sessions; however, the American
Psychiatric Association (2009) notes that time saving alternative intervention methods
such as telephone or computer assisted therapy are possible avenues that merit further
research.
Numerous studies have demonstrated the efficacy of using CBT for the treatment
of panic disorder (Barlow, Gorman, Shear, & Woods, 2000; Barlow, Craske, Cerney, &
Klosko, 1989; Clark, Salkovskis, Hackmann, Middleton, Anastasiades, & Gelder, 1994;
Craske, Brown & Barlow, 1991; Craske, DeCola, Sachs, & Pontillo, 2003; Craske, Lang,
Aikins, & Mystkowski, 2005; Telch, Lucas, Schmidt, Hanna, LaNae, & Lucas 1993).
Additionally, several meta-analyses of clinical trials have also supported the use of CBT
for panic disorder (Gould, Otto, & Pollack, 1995; Butler, Chapman, Forman, & Beck,
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2006; Mitte, 2005). Barlow et al. (2000) conducted the largest of these trials which
included 312 individuals who had been diagnosed with panic disorder. They compared
treatment groups that received CBT, imipramine (Tofranil), CBT and imipramine, CBT
and placebo, and placebo. They found that CBT was superior to placebo and comparable
to imipramine alone and CBT with imipramine combination intervention in reducing
panic symptoms at the end of the acute phase of treatment. After a 6-month maintenance
phase of continued medication and monthly CBT booster sessions, CBT alone was again
found to be superior to placebo and equivalent to imipramine. The combination of CBT
and imipramine treatment was found to be significantly superior to all other treatment
conditions at the end of this phase of the study. However, at the end of a 6-month followup phase after termination of all treatments the CBT and CBT plus placebo were the only
two treatment conditions that remained superior to placebo. Thus, this study
demonstrated the short and long-term efficacy of CBT for the treatment of panic disorder,
and it suggests that CBT without adjunctive pharmacological treatment is most likely to
produce durable reduction in panic symptoms. Additionally, this finding of sustained
beneficial effects for individuals who showed reduced panic symptoms as a result of
treatment with CBT has been replicated in other studies (Brown & Barlow, 1995; Craske,
Brown, & Barlow, 1991; Fava, Zielezny, Savron, Grandi, 1995).
Psychodynamic Psychotherapy. Aside from the numerous studies concerning the
use of CBT techniques, there has been relatively little research conducted regarding the
effectiveness of other behavioral health interventions (American Psychiatric Association,
2009). One exception is a study that appears to support the effectiveness of PFPP for the
treatment of panic disorder (Milrod et al., 2007). PFPP is a brief panic focused
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psychodynamic intervention model that consists of 24 bi-weekly sessions. During the
first phase of PFPP, the client and therapist work to uncover the unconscious meanings
behind panic symptoms in order to achieve a reduction in panic attacks and agoraphobia.
The second phase focuses on deepening the understanding of core unconscious conflicts
and altering these beliefs through techniques such as analysis of transference. Finally, in
the third phase the client’s reaction to termination issues allows them to re-experience
conflicts related to separation and anger. Although a resurgence of panic symptoms may
appear during this phase of treatment, articulating underlying feelings with the therapist
is theorized to help clients identify new abilities to manage these emotions and promote
autonomy. In a randomized controlled trial Milrod et al. (2007) compared the
effectiveness of PFPP and a manualized Behavioral Therapy program consisting of
applied relaxation with exposure training for the treatment of panic disorder. These
authors found that 73% of participants that were treated with the PFPP techniques
reported a significant reduction in panic symptoms versus 39% of those that were in the
applied relaxation treatment group. Although this is only a single study, the author
proposed that these preliminary promising findings suggest that further research should
explore whether PFPP could be a efficacious alternative to CBT in the treatment of panic
disorder.
Emotion-Focused Psychotherapy for Panic Disorder. Another possible
therapeutic treatment modality that has been investigated is EFPPD (Shear et al, 2001).
EFPPD was described as a brief treatment consisting of empathic listening and supportive
strategies that aim to help clients identify and manage painful emotions and troubling life
situations. These authors compared the outcomes for participants who participated in
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EFPPD to treatment groups who received CBT, imipramine (Tofranil) prescription, or
placebo. The response rate for imipramine and CBT treatment groups, 93% and 82%
respectively, showed comparable reductions in reports of panic symptoms. Additionally,
they found that the response rate for participants who received EFPPD was more similar
to that of the placebo treatment group, at 52% and 63%. One interesting caveat to this
study was that despite the demonstrated superior effectiveness of CBT and imipramine in
treating panic symptoms, treatment retention rates were highest for the EFPPD group.
Specifically, the acute and maintenance treatment was completed by 60% of participant
receiving EFPPD, 47% of those receiving CBT, 38% of those receiving placebo, and
13% receiving imipramine. It is not possible to determine if the differences in drop-out
rates were due to drug side-effects, dissatisfaction with treatment results, or other factors
related to treatment tolerability. However, the authors of this study suggested that the
lower attrition rate in conjunction with poorer response to treatment may actually be
related to avoidant and separation-anxiety tendencies commonly encountered when
treating individuals with panic disorder. They concluded that practitioners should closely
monitor effectiveness of the treatments they offer, and consider using CBT techniques in
order to safeguard against colluding with possible avoidant behavior.
Combination pharmacological and therapy intervention. As detailed above
both pharmacological and behavioral health interventions have demonstrated efficacy in
reducing the symptoms associated with panic disorder. It is not surprising then, that
many mental health professionals advocate a treatment approach that combines the use of
pharmacological and therapy interventions (Pollack, 2006). Specifically, many mental
health professionals and clients have sought to couple the fast relief of panic symptoms
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brought on by benzodiazepines with the sustainable treatment gains that have become
associated with CBT. However, research suggests that combining these treatment
modalities does not necessarily result in a beneficial additive effect. Instead, findings
indicate that CBT for the treatment of panic disorder with or without pharmacotherapy
yields similar results (Barlow, Gorman, Shear, & Woods, 2000; Schmidt, & Smith, 2005;
Westra, Stewart, and Conrad, 2002). Furthermore, there is also research that suggests
that the concurrent use of benzodiazepines with CBT actually results in fewer long-term
treatment gains (Brown & Barlow, 1995; Fava, et al., 1995; Westra, et al., 2004). Westra
and colleagues’ study found that participants from the combined benzodiazepine and
CBT treatment group retained about 20% less of the presented psychoeducational
material than their nonmedicated counterparts. Further, they found that chronicity and
frequency of use were not related to memory, but that greater time from peak blood-drug
concentration during the encoding task was associated with better recall. This evidence is
counter to beliefs that memory deficits associated with benzodiazepine use fade as
physiological tolerance is established. Additionally, Otto, Smits, and Reese (2006)
asserted that a combination antidepressant and CBT approaches for individuals with
panic disorder does not appear to have significant benefits over CBT alone, and CBT
shows superior long-term effectiveness when compared to antidepressant medication and
combined treatment groups. In conclusion, it appears that combination therapy may
significantly increase the cost, risks, and resources associated with treating pure panic
disorders without substantial evidence that of superior acute or maintenance efficacy and
limit the long-term gains.
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Organizational Change
According to Rogers (2003) an organization is “a stable system of individuals
who work together to achieve common goals through a hierarchy of ranks and a division
of labor” (p. 433). Predetermined goals, prescribed roles, rules, regulations, interactional
patterns, and configuration of authority are collectively known as the organizational
structure. This structure provides stability to the organization by encouraging individual
members to behave in a predictable and acceptable manner. However, the ability to cope
with innovation or change such as restructuring, outsourcing, or incorporating the use of
new techniques or technology, must also be a part of any viable organizational model
(Prochaska, Levesque, Prochaska, Dewart, & Wing, 2001). Since one of the aims of this
dissertation is to function as a translational research piece that promotes agency change, a
brief review of literature on diffusion of innovations and organizational change will be
helpful in understanding the methods and goals of this project.
Transtheoretical Model of Change. The Transtheoretical Model of Change has
its roots in research that addresses evaluating and affecting change readiness for
individuals with addictive behavior problems, but it has more recently evolved into a
popular integrative approach used to describe and promote individual and organizational
change (Prochaska & DiClemente, 1983; Prochaska, DiClemente, & Norcross, 1992;
Prochaska & Velicer, 1997). Its most recent version integrates a variety of existing
theoretical concepts including stage of change, decisional balance, self-efficacy, and
processes of change (Bandura, 1977; Janis & Mann, 1977; Prochaska & DiClemente,
1983; Prochaska & Velicer,1997). The first core construct, Prochaska and Diclemente’s
(1983) stage of change model, theorizes that people move through five distinct stages
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when they modify behaviors. These stages include: (a) The Precontemplation Stage,
which is characterized by the individual not intending to proceed with an action for the
foreseeable future (at least 6 months), (b) The Contemplation Stage that is described as
the period when people have an intention to take action within the next 6 months, (c) The
Preparation Stage, which is characterized by the intent to take action in the near future
(next 30 days), (d) The Action Stage, which is defined as the first six months of change
implementation, and (e) The Maintenance Stage which involves the ongoing process of
sustaining changes and preventing relapse. Research regarding a range of behaviors has
shown that the majority of individuals, typically about 80%, are in the precomtemplative
and contemplative stages (Laforge, Velicer, Richmond, & Owen, 1999; Velicer, et al.,
1995). Forced implementation of change during the contemplative and precontemplative
stages may lead to poor outcomes. Specifically, when organizational initiatives are not
stage-matched, they can create reactions such as resistance and defensiveness from
employees that are not ready for that level of change. This common scenario has been
cited as an important contributing factor in explaining why most organizational change
initiatives fail (Levesque, Prochaska, & Prochaska, 1999).
The concept of a decisional balance, which compares the pros and cons of change,
was originally proposed by Janis and Mann (1977). According to Prochaska and
Diclemente (1983), the construct of decisional balance is likely an underlying factor that
affects the level of intention that is classified by stage of change. It is theorized that
higher stages of change are characterized by a greater pro to con ratio; thus,
Transtheoretical Model of Change programs seek to increase the pros of changing while
decreasing the cons. Additionally, another factor that appears to correlate with stage of
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change is the concept of self-efficacy. Bandura (1977) described self-efficacy as the
degree to which people believed they had the capacity to attain a desired goal. Selfefficacy can influence an individual’s readiness for change by affecting their levels of
motivation and persistence (Levesque, Prochaska, & Prochaska, 1999). Moreover, higher
levels of self-efficacy appear to promote durability of change and safeguard against
relapse.
Prochaska and Diclemente (1984) identified 10 fundamental patterns of activity
that promote change readiness and action known as processes of change. These
processes of change include: consciousness raising, dramatic relief, self-reevaluation,
self-liberation, environmental reevaluation, reinforcement management, counterconditioning, helping relationships, stimulus control, and social liberation. Research
suggests that people in earlier stages of change, such as precontemplative and
contemplative levels, rely more on consciousness raising, dramatic relief, and
environmental reevaluation processes (Prochaska, Diclemente, & Norcross, 1992).
Individuals in the preparation stage are more influenced by self-evaluation and selfliberation techniques, and persons who reached the action and maintenance phases relied
more heavily on reinforcement management, helping relationships, counter-conditioning,
and stimulus control processes in order to complete and sustain change. Although the
activities described above are part of the natural process that individuals may go through
when considering change, these processes may also be used by change agents in order to
encourage or elicit behaviors that promote a desired organizational change. Levesque,
Prochaska, and Prochaska (1999) proposed that interventions should be individualized by
matching and the organizational members’ readiness to change with the indicated process
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of change. For example, if the organization has determined that the majority of its
members are in the contemplative and precontemplative stages of readiness for change,
the organization might utilize consciousness raising techniques such as sending out
newsletters or memos that can increase the awareness of the proposed change and its
benefits. By utilizing this type of stage-matched intervention, the researchers claimed
that the organization can reduce resistance, stress, and time needed to implement a
desired change by superficially accelerating the natural movement toward the action
phase. Conversely, they suggest that using a change process that is too advanced for the
individual members’ readiness is likely to result in increased resistance and resentment.
Thus, appropriately matching the stage and process of change is important in order to
optimize the conditions for change and maximize the chances of implementing a
successful and durable change within organizations.
Diffusion of Innovation Model. Innovations are ideas that are perceived as new
and different, and diffusion is the process by which innovative ideas spread through a
social system over time, via various communication channels (Rogers, 2004). The
Diffusion of Innovation Model was developed in the 1950s in response to agricultural
research regarding the dissemination of knowledge and usage of new heartier and high
yield hybrid corn seeds in Iowa (Rogers, 2004; Rogers, 2003; Ryan & Gross, 1943). The
Iowa hybrid seed corn study showed that earlier adopters of the innovative farming
techniques shared some important characteristics. These farmers were generally found to
have larger farms, higher incomes, and more education. Additionally, early adopters
made more frequent trips to Des Moines, and they were more likely to have a neighbor
who was using the hybrid seed method. The findings from this and subsequent
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agricultural research studies revealed an information-exchange process that was central to
the diffusion of innovations. Specifically, it was theorized that early adopting farmers
had more opportunities for exposure to communication that could increase awareness and
knowledge of potential benefits for using the new corn planting method.
Rogers (2004; 2003) continued the work related to studying agricultural diffusion
for his dissertation in 1957. However, as he encountered similarities in literature related
to the process of implementing change in other types of systems such as schools, he
became convinced that he had discovered a more generalizable model of change. In
1962, he introduced the idea of a general diffusion model in his book, Diffusion of
Innovations. To date, five subsequent editions of the book have been published, and
research based on this model has been produced by marketing scholars, public health
researchers, political scientists, and anthropologists.
According to Rogers (2003), decisions about whether or not an individual or
organization will adopt a potential innovative practice is a process that occurs over time
and can be understood as a series of stages. The first stage, knowledge, occurs when the
decision making unit gains awareness of an innovation’s existence and an understanding
of how it functions. This may be preceded by the identification of a specific need that the
innovation addresses, or exposure to the innovation may promote a desire to adopt it such
as is common with consumer goods. During the next stage, persuasion, a favorable or
unfavorable impression regarding the innovation is formed. This stage is characterized
by active engagement and knowledge seeking in order to evaluate the innovation’s
potential advantage, compatibility, and complexity for the potential adopter. The third
stage, decision, is characterized by engagement in activities that lead to a choice to adopt
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or reject the innovation. For example, the potential adopter may try the innovation on a
partial or trial basis in order to facilitate this step in the process. Implementation, the
fourth stage, occurs when the system puts a new idea into action. This is typically a
tenuous part in the process since implementers generally continue to have apprehension
about potential consequences at this stage. Change agents may help to facilitate the
implementation of innovations by offering information and technical assistance. The
final stage, confirmation, takes place when the decision making unit seeks reinforcement
of the innovation-decision. If exposed to conflicting messages about the innovation, the
decision making unit may reverse the previous innovation-decision. Additionally, it is
important to note that each stage is a potential point for rejection or re-invention of the
proposed innovation. Re-invention, or modification of the innovation by adopters, is not
necessarily a bad thing. It can actually lead to beneficial customization and a greater
sense of personal investment that may help to encourage a stakeholder mentality among
individual group members.
Although the Diffusion of Innovations Model was originally designed as a
generalization about the spread of new ideas among individuals, it has also been adapted
to serve as a template for innovating in organizations (Rogers, 2004). As previously
mentioned, an organization is a system of individuals who work together via prescribed
roles, rules, and division of labor in order to achieve predetermined common goals
(Roger, 2003). Depending on the structure of the organization and the nature of the
proposed new idea, innovation decisions fall into three categories: optional innovationdecisions, collective innovation-decisions, and authority innovation-decisions. An
optional innovation-decision can be made by individuals within an organization
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regardless of decisions made by other members. A collective innovation-decision is
made by a majority of a system, but compliance is mandatory for all members once the
innovation is adopted. An authority innovation-decision is made by relatively few high
powered organization members, but it is mandatory for all organization members.
The innovation process for organizations also consists of five stages: agendasetting, matching, redefining/restructuring, clarifying, and routinizing (Rogers, 2003).
The first stage, agenda-setting, is a constant process of defining and prioritizing problems
that need to be addressed within an organization. Matching, the second stage, happens
when an innovation is identified that will be used to address the problem. The next stage,
redefining/restructuring, occurs when the innovative idea and the organization’s structure
are both modified to ensure that there is a good fit between innovation and organization.
The fourth stage, clarifying, allows members of an organization to construct their own
meaning and understanding of the innovation through widespread implementation. In the
final stage, routinizing, the innovation loses its separate identity and becomes an accepted
regular function of the organization.
According to Rogers (2003), the innovation process for organizations is much
more complex than that for individuals. This is in part due to the sheer number of
individuals within the larger system who may have an active role in the innovationdecision and implementation processes. Individuals who have earned and maintained a
high degree of technical competence, social accessibility, and conformity to the system’s
norms are more likely to be opinion leaders. These persons are frequently able to
influence the attitudes and behaviors of others by acting as social models or using well
developed communication skills. An individual that represents a change agency external
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to the organization is known as a change agent. Change agents provide an important
communication link between a resource system and a client system. Examples of change
agents are teachers, public health workers, agricultural extension agents, salespeople, and
development workers. Change agents seek to influence the client’s innovation-decisions
toward the change agency’s desired outcome, and they often attempt to recruit opinion
leaders to further their cause. When a charismatic person within the organization
endeavors to promote the adoption of new ideas they are referred to as an innovation
champion. Innovation champions contribute the likelihood of success of an innovation
within the organizational setting by addressing indifference and resistance among their
peers.
Organizational change in community mental health settings. There has been
little research published specifically regarding the implementation of change in
community mental health settings. However, Schulz and Greenberg (1995) proposed one
theory and framework for evaluating the implementation of change related to their
innovative project aimed at the improvement of the quality of life for persons with severe
and persistent mental illnesses. They posited that environmental, organizational, and
change agent characteristics are all forces that interact and influence change to varying
extents. Additionally, they suggested that these forces also interact with the innovation
and change itself in a multidirectional manner.
The environmental factors that are likely to impact the change process are the
culture, stability, and structure of the environment (Schulz & Greenberg, 1995). The
broader culture in which a community mental health clinic is embedded influences the
diagnosis, care, and acceptance of mental illness for the client population that the agency
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serves. The relative structure and stability within which an agency operates will also
likely affect the likelihood of promoting or resisting change. For example, a community
that values formality and stability is more likely to resist change than one with informal
structure that is used to implementing changes.
Organizational aspects proposed to influence implementation of change are
culture, stability, structure, resources, and interest groups (Schulz & Greenberg, 1995).
The organizational culture, or the shared values and mission of an agency, is likely to
impact the way that staff regard proposed changes to client care. Additionally, the
stability and structure of the organization can also impede or promote innovation. The
availability of agency resources such as travel and time for further training could be
another factor that may influence the adoption or rejection of a proposed change within
the community mental health setting. Finally, Schulz and Greenberg (1995) also
suggested that key interest groups such as unions or members of different professions
were likely to have different perceptions of the change and its potential benefits and
consequences. Thus, these groups may either advocate for or resist change based on their
unique perspectives.
Schulz and Greenberg (1995) also proposed that change agents’ personal
characteristics, influence and resources, strategies used, and manner of assisting the
organization in implementing change are important in effecting successful change. These
authors asserted that personal characteristics like vision for the agency, motivation to
affect change, and the ability to influence others are essential ingredients in promoting
adoption of an innovation. Another key consideration is the change agent’s ability to
gain control over resources needed for the implementation of the proposed innovation;
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therefore, support from the executive levels of an organization were found to be highly
beneficial. Additionally, it is important that the change agent has an implementation
strategy that incorporated knowledge about the agency’s and the community’s cultural
factors to decrease the chances of resistance and rejection of the change. Some change
agents may also influence the likelihood of successful adoption of innovations by
assisting those in the organization who are responsible for directly implement those
changes.
The above outlined theories of change and innovation have significant overlap;
therefore, for the purposes of this dissertation project, they will be used in an integrative
manner. For example, Rogers (2003) asserted that his five stages of the innovationdecision process can be thought to correspond directly to five phases in Prochaska and
Diclemente’s (1983) stages of change model. By utilizing information from both of these
models, individualized stage-matched interventions can be identified and utilized in this
translation research. Additionally, Schulz and Greenberg’s (1995) framework will be
used to add in considerations that are specific to the organizational structure and purpose
of community mental health agencies.
Overview
Although it is evident from the preceding literature review that there has been a
considerable amount of research devoted to the exploration of effective treatments for
panic disorders, it is also notable that there is a dearth of translational research regarding
this topic. Most research has been conducted in highly controlled settings with rigorously
screened client populations; however, conditions are typically much more complex in real
life settings such as community mental health agencies. Furthermore, longitudinal
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studies have shown that despite recommendations to the contrary, benzodiazepines
continue to be prescribed more often than other pharmacological or behavioral treatment
methods. Thus, there is a clear need for further translational research that takes into
consideration factors related to implementing innovative best practice recommendations
for treating panic disorder in organizations.
This dissertation also explored the diffusion of innovations regarding the
treatment of panic disorder in a community mental health agency. Specifically, this study
captured a profile of current knowledge, skills, attitudes, and practices within a large
metropolitan community mental health agency, and examined potential options and
dilemmas involved in implementing innovative or best practice guidelines for the
treatment of panic disorder. The project utilized methods including database analysis and
record review to formulate an accurate profile of the agency’s current treatment practices.
Additionally, a survey of key personnel that influence client care was used to generate
information that provided information regarding the organization’s view of the potential
need for innovative panic disorder treatment practices and possible obstacles or
impediments for implementing changes in treatment standards. The results of this
investigation are discussed in light of organizational change literature and what current
results imply regarding successful treatment strategies for panic disorder in a community
mental health setting. The findings from this study also were used to produce a report for
the participating agency that included a detailed summary of their current panic disorder
treatment practices and a clear profile of knowledge, skills, and attitudes regarding the
management of panic disorders held by different key agency sub-groups. These findings
also are compared to the existing literature base on organizational change in community
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mental health systems to generate possible implications for future action and
recommendations.
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Methods
In order to capture a profile of the knowledge, skills, attitudes, and practices
within a large metropolitan community mental health agency, and examine potential
options and dilemmas involved in implementing innovative or best practice guidelines for
the treatment of panic disorder, this project utilized two types of information gathering
techniques. The first method included a survey of client care providers at the participating
agency, and the second involved a database analysis of client demographic and outcome
figures. The methods and participants of these information gathering strategies are
explained below.
Phase One Method: Panic Disorder Treatment Survey
First, an online survey (Appendix A) was designed and administered to key
personnel that influence client care. The survey was used to provide an overview of the
knowledge, skills, and attitudes of treatment providers at the participating agency.
Additionally, it generated information regarding the organization’s view of the potential
need for innovative panic disorder treatment practices and possible obstacles or
impediments for implementing changes in treatment standards.
Participants. In total, 46 client care personnel and administrators completed the
survey. The total number of administration and client care employees available to take
the survey was 170; thus, a response rate of 27% was achieved. The majority of
participants (78%) were female (36 females, eight males, and two undisclosed).
Similarly, the agency reported that majority of the employees (85%) at their agency that
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were eligible to complete the survey were female (145 females and 25 males). Age was
reported via response to a multiple choice question with 10 year increments on the
survey, and participants’ reported ages ranged from 20s to 60s. Slightly greater than a
third of the respondents indicated their age was in the 31-40 years old age range (n=16).
However, the rest of the participants were relatively evenly distributed among the 21-30
(n=9), 41-50 (n=5), 51-60 (n=11), and 61-70 (n=5) age ranges. It appears that the ages of
survey participants was a good representation of client care population at the participating
agency which was also relatively evenly distributed among the 21-30 (n=39), 31-40
(n=47), 41-50 (n=38), 51-60 (n=30), and 61-70 (n=16) year age ranges.
Approximately 61% (n=28) of the respondents indicated their highest completed
educational degree as a master’s degree compared to 55% (n=94) of the total client care
population that the participating agency. The remaining participants indicated educational
attainment levels of associates, bachelors, and doctorate degrees, and each of these
degreed groups represented 13% (n=6) of the total participants surveyed. Likewise, the
agency reported a much lower number of employees with highest educational attainment
levels of associates (n=30), bachelors (n=32), and doctorate (n=14) degrees than master’s
degree employees (n=94). The sample consisted of respondents from disciplines
including counseling (n=19), social work (n=13), nursing (n=7), psychology (n=6), and
medicine (n=4). Two participants indicated “other” as their professional discipline (see
Figure 1). This number is identical to that of respondents indicating that their practice
area was administration without client care; therefore, these respondents are likely
professionals from disciplines related to business operations. The agency also provided
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similar data on the number of staff by discipline for counseling (n=80), social work
(n=52), nursing (n=10), psychology (n=9), psychiatry (n=10), and administration (n=9).
Overall, the demographic data provided by the survey respondents indicated that a
representative sample of the key personnel that influence client care at the participating
agency had been reached. Thus, data collected from survey questions regarding
knowledge, attitudes, skills, and practice should be useful for in creating an overall
agency profile, and also for examining similarities and differences between subgroups of
client care personnel such as by discipline, practice area, sex, or educational level of
agency employee.
Instrument. The online survey was designed and administered utilizing the
SurveyMonkey web-service. The survey was a 50-item instrument that included
questions with yes/no, multiple choice, and 4 point Likert type answers. The instrument
included questions regarding demographic information such as age, sex, gender,
educational level, and clinical practice area. Additionally, the survey asked participants to
indicate their level of training and clinical experience with treating individuals with panic
disorder. Additionally, client care personnel were asked to provide their opinions about
the level of safety and effectiveness for different types and combinations of therapy and
pharmacological interventions for panic disorder. Specifically, the therapy treatment
modalities rated included behavioral exposure, cognitive behavioral therapy, panic
focused psychodynamic psychotherapy, and emotion-focus psychotherapy for panic
disorder. The psychopharmacological interventions considered were antidepressants
(Prozac, Lexapro, Effexor, etc.) and benzodiazepines (Xanax, Ativan, Klonopin, etc.).
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The survey instrument also included a section that explored knowledge and
attitudes regarding the nature, course, prognosis, and treatment considerations for
individuals with panic disorder. In this section, the participants were asked to rate their
own level of knowledge and training related to treating clients with panic disorder as well
as agency practices of referral and treatment. The respondents were also asked to
indicate their agreement with statements concerning likelihood of client motivation,
compliance, and relapse in response to different treatments. Moreover, these items
explored attitudes and knowledge regarding potential treatment issues related to tolerance
for psychotherapeutic intervention and drug dependence or abuse.
Procedure. The participating agency asked its client care employees to complete
the online survey. Administration and department managers utilized a script that was
designed by the researcher and agency officials (and approved by the agency’s quality
department and the researcher’s university) to explain the survey portion of this research
through emails and department meetings. This script can be found in Appendix B. The
web address and hyperlink to the survey was provided in the email sent out to all eligible
client care employees. The agency personnel were allowed to complete the survey over a
1- month time span at their convenience on any available computer. The agency’s
administrators and managers decided to encourage all of their employees to participate in
the survey so that they could gain information about panic disorder treatment opinions
and practices among their employees. Thus, an incentive was offered in the way of a
drawing for one of four $50.00 Amazon.com gift cards. The survey included an item
allowing employees to voluntarily consent or refuse the use of their survey answers for
this research and potential publication. The survey responses were then filtered by the
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answer to the consent item, and only those respondents that consented to have their
answers used for research were used for this dissertation project. Thus, the 46 participants
of this research project refers to the individuals that agreed to allow their answers to be
used for research and publication purposes from the total 52 survey respondents. As an
incentive for participation in this research project, individuals were given the ability to
follow a hyperlink that was embedded in the online survey in order to register for a
chance at one of four $50 gift certificates. These certificates were awarded to individuals
through a random drawing.
Data Analysis. After the responses were collected and filtered by consent to
participate in this research project, the resulting data were downloaded and analyzed
using the NCSS, 2007 Edition statistical software. Additionally, charts and tables were
constructed utilizing Microsoft Excel tools. Both one-way analysis of variance
(ANOVA) and goodness-of-fit (chi-squared) statistical analysis were used to summarize
findings and describe the relationships between demographic variables and knowledge,
attitude, skills, and practices.
Phase Two Method: Database Review
This project also utilized a database analysis of client diagnostic, treatment
modalities and duration, as well as pre and post functional ability scores to formulate an
accurate profile of the agency’s current treatment practices and outcomes. A formal plan
(Appendix C) for collecting and aggregating this information from client electronic
charting records was devised with a representative from the agency’s quality department
and approved by the participating agency and the researcher’s university for this
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dissertation project. The resulting summary data were used to gain a better understanding
of current panic disorder treatment practices.
Participants. The total number of active and terminated cases reviewed for
possible inclusion in this database summary was 7,828 (active n=3,884; terminated
n=3,944). The time period sampled included 3 years prior to the current study. In order
to decrease the number of diagnostic and treatment variables considered for this project,
only client records with panic disorder only (with or without agoraphobia) were included
in the database review for this project. Of those potential cases, 248 records showed a
diagnosis of panic disorder and 139 records indicated a diagnosis of only panic disorder.
It is the practice standard of the participating agency not to provide medication services
to clients who are not concurrently enrolled in therapy. Therefore, the treatment
conditions that were identified were therapy only and therapy with benzodiazepine
medication services. Of the panic disorder only cases, 19 received therapy only, while
119 received a combination of benzodiazepine medication and therapy. This sample was
further refined to include only clients who had terminated during the 3-year time period
reviewed in order to assess treatment outcomes such as differences in pre and post GAF
scores and duration of treatment in months. The total number of participants in the
therapy and benzodiazepine medication group was 20, while only five cases received
therapy alone for panic disorder.
Procedure. Three years of client electronic charting information was sanitized of
identifying information and compiled into summary reports according to treatment
modality. In order to create a data summary that could be compared to current best
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practice standards, the diagnostic and treatment variables outline above were used to
refine the database search.
Data Analysis. After the database summary was compiled and sanitized of
patient identifying information by the agency representative, the resulting data were
analyzed by again utilizing NCSS, 2007 Edition statistical software. Descriptive
statistical analysis was completed to summarize and compare diagnostic and treatment
information with outcomes and duration of treatment. The findings of this database
review were compared to literature regarding best practices to generate inferences about
effectiveness of the agency’s current practices and produce recommendations for
potential future directions.
In sum, the methods outlined above were designed to capture an accurate profile
of the knowledge, skills, attitudes, and practices related to the treatment of individuals
with panic disorder at the participating agency. However, the collection of data in this
project was meant to represent a “case in point,” and the information gathered from the
participating agency was compared with existing research about best practices for
treating panic disorder. Furthermore, classic organizational change literature and research
regarding program change within community mental health organizations was helpful in
formulating inferences about and implications of the data collected in this project.
Finally, it is the researcher and participating agency’s wish that the findings produced by
the extensive methods outlined above will contribute to the current dearth of translational
research regarding panic disorder treatment and outcomes in a real world clinical setting.
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Results
The data resulting from the two phases of investigation in this study were
analyzed with the use of NCSS statistical software in order to test the significance of
findings for the key variables of interest. For the purposes of this study, differences were
determined to be significant if they reached the .05 level of significance (p < .05). In the
first phase of this study, the agency survey on panic disorder treatment knowledge, skills,
and attitudes, was analyzed to determine the presence of any significant differences
among client care cohorts. A chi-squared (χ2) goodness of fit test was performed on the
categorical data collected from the survey, and one-way analysis of variance (ANOVA)
was used for the Likert scored data. A Tukey-Kramer post-hoc test was also utilized
during analysis in order to adjust for potential sources of error such as unobservable
latent variables when examining variance between groups. This step was useful in
describing the direction and strength of the relationships between the multiple variables
being analyzed in this study. Additionally, tables and figures such as box plot graphs
with indicated means, ranges, and outliers, were utilized to visually represent results.
Cohorts that were examined in this study included groups that varied by discipline,
highest educational level, age, and reported extent of panic disorder specific training.
The second phase of investigation included the collection of client treatment data,
which were analyzed for differences between pre- and post-treatment among clients
receiving therapy alone and those receiving a combination of therapy and benzodiazepine
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medication for the treatment of panic disorder. Pairwise differences for these two
treatment groups were analyzed using t-tests.
Phase One Results: Panic Disorder Treatment Survey
During the initial analysis of the survey responses, the overall results were
considered to identify areas of participant agreement and potential themes (Appendix D).
For example, the majority of participants surveyed indicated that they had received
training in treating panic disorder through readings (n=32, 71.1%), coursework (n=28,
62.2%), and supervision (n=23, 51.1%), while slightly fewer had participated in training
workshops (n=22, 48.9%) on the topic. There was also considerable agreement among
participants about the percentage of clients from their case loads that had only a diagnosis
of panic disorder, with the majority indicating that only 0-5% (n=29, 65.9%) or 5-10%
(n=6, 13.6%) of their clients fit that description. Additionally, most respondents indicated
some level of agreement (a combination of strongly agree and somewhat agree figures
responses) that they felt they had enough knowledge/training about panic disorder
treatment (n=39, 84.7%), and they thought their own and the agency’s practices were safe
and effective (n=41, 93.2% and n=42, 93.3% respectively). The majority of participants
(n=36, 78.3%) also indicated agreement with the following statement: “clients presenting
with panic disorder should be referred for psychotherapy before being referred for
medication.”
Overall results of items that asked about the safety and effectiveness of different
therapy treatment approaches for panic disorder revealed several areas of general
consensus among participants. When asked which therapy approach was safest and most
effective, most participants chose cognitive-behavioral therapy (n=23, 79.3% and n=18,
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60% respectively). The majority of participants also indicated that cognitive-behavioral
therapy was the most similar therapy approach to their own (n=25, 83.3%) and the one
with which they had the most training and experience (n=25, 83.3%). Most participants
were least familiar with panic focused psychodynamic psychotherapy (n=23, 76.7%).
The majority of respondents indicated they thought panic focused psychotherapy (n=13,
46.4%) and emotion-focused psychotherapy for panic disorder (n=11, 39.3%) were the
least effective therapy approaches. However, behavioral therapy (n=12, 46.2%) was
selected by more participants as the least safe approach, compared to panic focused
psychotherapy (n=10, 38.5%) and emotion-focused psychotherapy for panic disorder
(n=4, 15.4%).
There was also agreement found among many of the participants for items
regarding medication treatment for panic disorder. For example, most survey
respondents indicated that they thought antidepressants (n=31, 81.1%) were the safest
medication for treating the panic disorder, and benzodiazepines (n=33, 86.8%) were the
least safe medication treatment. Additionally, more respondents chose antidepressants
(n= 17, 45.9%) over benzodiazepines (n=11, 29.7%) as the most effective medication for
treating panic disorder. Most respondents also indicated agreement (strongly agree and
somewhat agree response figures collapsed) with the following statements about potential
issues with benzodiazepine prescriptions: “benzodiazepines build dependency” (n=42,
91.3%); “some clients may abuse or sell their benzodiazepine prescription medications”
(n=43, 93.4%); and “clients prescribed benzodiazepine medications for their panic
disorder, may not attend psychotherapy appointments regularly” (n=35, 76.1%).
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On survey items about combination therapy and medication approaches,
participants were asked to consider treatment options including therapy alone, medication
alone, a combination of therapy and benzodiazepine medication, and a combination of
therapy and antidepressant medication. Most participants favored antidepressant
medication with therapy for the treatment of panic disorder in regards to safety (n=30,
78.9%) and effectiveness (n=22, 57.9%). Medication alone was indicated as the least
safe (n=24, 63.2%) and least effective (n=23, 60.5%) of the approaches outlined.
However, many items that did not yield a consensus opinion, and examination of
the overall results leads to a hypothesis that differences may exist between specific
participant cohort groups. Thus, further statistical analysis of the responses collected
from the 46 client care and administrative personnel participants who completed the
panic disorder treatment survey focused mainly on identifying differences between
cohorts in answering questions regarding knowledge, skills and attitudes on the treatment
of panic disorder. Participant cohorts that were explored in this study were defined by
variables including highest educational level attainment, discipline, practice area, and
types of professional training they had received in treating panic disorder.
Discipline. The first cohort variable was that of professional discipline. The
survey respondents included 10 social workers, 18 counselors, seven nurses, four
psychiatrists, and five psychologists. Two participants could not be included in the
analysis by discipline because they chose not to answer this survey item. Due to the
small number of participants who identified as nurses and psychiatrists, these respondents
were collapsed into a single discipline variable that will be referred to as “medical” in
order to improve the statistical accuracy of analysis. Combining these groups of
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respondents makes sense since the psychiatric nurses at this agency work closely with the
psychiatrists surveyed and their job duties include monitoring, and in the case of the
nurse practitioners, prescribing psychotropic medications. When survey responses were
analyzed by discipline, several significant findings emerged. The breakdown of
respondents by discipline is shown in the Figure 1:
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Figure 1. Percentages of Participants by Discipline.

For survey items regarding the perceived safety and effectiveness of different
types of treatment for panic disorder there were two significant finding of difference
among the discipline groups identified. For example, the one-way analysis of variance
(ANOVA) comparing discipline with judged safety and effectiveness of antidepressant
medications for the treatment of panic disorder, showed significant differences between
disciplines, F(3,32) = 2.93, p =.048. A Tukey-Kramer post-hoc comparison of the four
groups showed that the psychologists (M = 2.4) indicated significantly less agreement
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with the survey item positing the safety and effectiveness of antidepressant medications
for the treatment of panic disorder, than the counseling and medical groups respectively
(Ms =1.67 and 1.4). The result of this first analysis appears in the Table 1 and Figure 2:

Table 1
Statistical Analysis of Responses to Item: Regarding the treatment of panic disorder, I
believe antidepressant medications are safe and effective.

Analysis of Variance

Between
Within
Total

Group
Social Worker
Counseling
Medicine
Psychologist

Sum of
Squares
3.372
12.267
15.639

Count
6
15
10
5

Mean
Square
1.124
0.383
-----

Df
3
32
35

F-Ratio
2.93
---------

Probability
Level
0.048
---------

Tukey-Kramer Multiple-Comparison Test
Mean
Different from Groups
1.667
----1.667
----1.4
Psychologist
2.4
Medicine

49

Strongly Disagree 4.00

Somewhat Disagree 3.00

Somewhat Agree 2.00

Strongly Agree 1.00

Social
Workers

Counseling

Medical

Psychologists

Figure 2. Response to item: “Regarding the treatment of panic disorder, I believe
antidepressant medications are safe and effective.”

Turning to the next tabled analysis shown in Table 2 and Figure 3, one can see
that there was also a significant difference in agreement among disciplines on the survey
item stating that therapy alone is a safe and effective treatment for panic disorder, F(3,
32), p = .017. On this item, Tukey-Kramer post-hoc analysis revealed that the
psychologist group (M = 1.2) indicated a significantly higher level of agreement than the
social workers, counselors, and medical groups respectively (Ms = 2.127, 2.4, and 2.3).
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Table 2
Statistical Analysis of Responses to Item: Regarding the treatment of panic disorder, I
believe therapy alone is safe and effective.

Analysis of Variance Table

Between
Within
Total

Sum of
Squares
5.667
15.333

Group
Social Worker
Counseling
Medicine
Psychologist

Mean
Square
1.889
0.479
-----

Df
3
32
35

F-Ratio
3.94
---------

Probability
Level
0.017
---------

Tukey-Kramer Multiple-Comparison Test
Count
Mean
Different from Groups
6
2.167
----15
2.4
Psychologist
10
2.3
Psychologist
5
1.2
Counseling, Medical

Strongly Disagree 4.00

Somewhat Disagree 3.00

Somewhat Agree 2.00

Strongly Agree 1.00

Social
Workers

Counseling

Medical

Psychologists

Figure 3. Responses to item: Regarding the treatment of panic disorder, I believe
therapy alone is safe and effective.
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In a somewhat related item, discipline was associated with a highly significant
degree of difference, F(3. 32), p = .005, regarding the statement: “When psychotherapy
has been effective for patients with panic, they will not tend to relapse.” Again, post hoc
analysis revealed that the variance was accounted for by differences between the
psychologist group (M = 1.8) and the medical and social worker groups (Ms = 2.727 and
2.9).

Table 3
Statistical Analysis of Responses to Item: When psychotherapy has been effective for
patients with panic, they will not tend to relapse.

Analysis of Variance Table

Between
Within
Total

Group
Social Worker
Counseling
Medicine
Psychologist

Sum of
Squares
5.118
13.882
19

Mean
Square
1.706
0.347

Df
3
40
43

F-Ratio
4.92
---------

Probability
Level
0.005
---------

Tukey-Kramer Multiple-Comparison Test
Count
Mean
Different from Groups
10
2.9
Psychologist
18
2.333
----11
2.727
Psychologist
5
1.8
Social Worker, Medicine
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Strongly Disagree 4.00
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Somewhat Agree 2.00
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Figure 4. Responses to Item: When psychotherapy has been effective for patients with
panic, they will not tend to relapse.

As seen in the next results table, analysis of the level of agreement among
discipline cohorts with another statement: “Benzodiazepine medications interfere with
successful psychotherapy,” also demonstrated a highly significant level of difference,
F(3.32), p = .008 among disciplines. Post-hoc analysis showed that the psychologist
group (M = 1.4) indicated a significantly greater level of agreement with that statement
than did the social worker, medical, and counseling groups (Ms = 2.8, 2.727, 2.667).
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Table 4
Statistical Analysis of Responses to Item Stating: Benzodiazepine medications interfere
with successful psychotherapy.

Analysis of Variance Table

Between
Within
Total

Group
Social Worker
Counseling
Medicine
Psychologist

Sum of
Squares
7.814
22.982
30.795

Mean
Square
2.605
0.575

Df
3
40
43

F-Ratio
4.53
---------

Probability
Level
0.851
---------

Tukey-Kramer Multiple-Comparison Test
Count
Mean
Different from Groups
10
2.8
Psychologist
18
2.667
Psychologist
11
2.727
Psychologist
5
1.4
Social Worker,
Counseling,
Medicine
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Figure 5. Responses to Item Stating: Benzodiazepine Medications interfere with
successful psychotherapy.

Regarding the statement: “Clients prescribed benzodiazepine medications for their
panic disorder may not attend psychotherapy appointments regularly,” a one-way
analysis of variance revealed another significant difference among discipline groups, F(3,
32), p = .038. The Tukey-Kramer’s post-hoc analysis of this item revealed that the
significant variance was accounted for between the psychologists (M = 1.2), who
indicated a much higher level of agreement with that statement, and the social worker
group (M = 2.4) who did not indicate as much agreement with it.
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Table 5
Statistical Analysis of Responses to Item Stating: Clients prescribed benzodiazepine
medication for their panic disorder may not attend psychotherapy appointments
regularly.

Analysis of Variance Table

Between
Within
Total

Sum of
Squares
5.414
23.382
28.795

Group
Social Worker
Counseling
Medicine
Psychologist

Count
10
18
11
5

Mean
Square
1.805
0.585

Df
3
40
43

F-Ratio
3.09
---------

Probability
Level
0.678
---------

Tukey-Kramer Multiple-Comparison Test
Mean
Different from Groups
2.4
Psychologist
2
----1.727
----1.2
Social Worker

Strongly Disagree 4.00

Somewhat Disagree 3.00

Somewhat Agree 2.00

Strongly Agree 1.00

Social
Workers

Counseling

Medical

Psychologists

Figure 6. Responses to Item Stating: Clients prescribed benzodiazepine medication for
their panic disorder may not attend Psychotherapy appointments regularly.
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Turning from the Likert scaled items to the categorical response items, the results
of the chi-square test of goodness-of-fit analysis on the question of whether the
participants thought either benzodiazepines or antidepressants were safer for treating
panic disorder appears below. Ratings for safety for the two medications were not equally
distributed in the population, χ2 (6, N = 36) = 13.543, p = .035, and there appears to a
significant relationship between discipline and perceived safety of different classes of
medications. While most participants (87%) from the social worker, counseling, and
medical disciplines appeared to favor antidepressant medications in regards to safety,
over half (60%) of the participants from the psychologist group endorsed neither
medication as the safest approach for treating panic disorder.
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0
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Figure 7. Responses to Item: Regarding the treatment of panic disorder, I believe the
following medications are safe and effective.
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In another item that was analyzed using the chi-squared test, participants were
asked to indicate which therapy approach they thought was safest: behavioral therapy,
cognitive-behavioral therapy, panic focused psychodynamic psychotherapy, or emotion
focused therapy. Participants’ endorsements for safest therapy was not equally distributed
among disciplines, χ2 (9, N = 29) = 17.068, p = .047, and there appears to a significant
relationship between discipline and perceived safety of different therapy approaches.
Specifically, although the majority of participants from the social worker (83%),
counseling (75%), and psychology (100%) groups endorsed cognitive-behavioral therapy
as the most safe and effective therapy approach, half (50%) of the respondents from the
medical group favored panic focused psychodynamic psychotherapy.
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Figure 8. Response to item: “Regarding the treatment of panic disorder, I believe the
following therapies are safe and effective.”
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Two other items that resulted in significant chi-square results involved familiarity
with different combinations of medications and therapy for the treatment of panic
disorder. Potential responses included therapy only, medication only, therapy and
benzodiazepine, therapy and antidepressant, all of the above, or none of the above. The
first item that indicated a highly significant level of difference, χ2 (15, N = 36) = 34.269,
p = .003, among discipline cohorts, asked participants to indicate the approach with
which they were most familiar. Most disciplines appeared to be most familiar with
therapy and medication or all of the combination treatments, while the majority of the
psychologist group cohort was most familiar with a therapy only approach to treating
panic disorder.
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Figure 91. Responses to the Item: With which of these approaches are you most
familiar?
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The item regarding the least familiar combination of treatments offered the same
potential responses, and a goodness-of-fit test was also highly significant, χ2 (15, N = 36)
= 33.527, p = .004. On this item the medical cohort group appears to differ most from
the other disciplines. The medicine group indicated least familiarity with the therapy
only approach, while the psychology and counseling groups appeared to be the least
familiar with a medication only approach.
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Figure 2. Responses to the Item: With which of these combined approaches are you least
familiar?

Educational Level. The second variable by which cohorts were grouped was
educational level. Survey participants were asked to indicate their highest level of
education completed or degree attained. Responses ranged from Associate’s degree to
Doctoral Degree. Specifically, participants included six individuals with an associate’s
degree, six with a bachelor’s degree, 28 with a master’s degree, and six who had
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completed a doctoral degree. When the data for survey participants was analyzed by
cohorts, several significant differences in reported knowledge skills, and attitudes
emerged. The distribution of participants is presented in the Figure 11:

Doctorate

Master

Bachelor

Associate

0%

10%

20%

30%

40%

50%

60%

70%

Figure 3. Percentages of participants by highest earned educational degree.

For survey items regarding the perceived safety and effectiveness of different
types of treatment for panic disorder, there were several significant findings when
participants’ responses were analyzed by educational attainment cohorts. For example, a
chi-squared goodness-of-fit test showed a significant difference, χ2 (6, N = 28) = 15.605,
p = .016, among cohorts when asked to choose the least effective therapy approach from a
list including: behavioral therapy, cognitive-behavioral therapy, panic focused
psychodynamic psychotherapy, and emotion-focused psychotherapy for panic disorder.
Although participants from the doctorate and master level cohorts seemed to lack
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confidence in panic focused psychodynamic and emotion-focused psychotherapies,
responses from the master’s degree group also indicated doubts about the effectiveness of
behavioral therapy. The bachelor’s degree cohort responses were evenly distributed
between cognitive-behavioral and emotion-focused therapy approaches.
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Figure 4. Responses for the item regarding the least effective therapy approach for the
treatment of panic disorder.

When educational cohort response regarding the “least safe therapy approach”
for treating panic disorder was analyzed for goodness-of-fit, another significant
difference was found, χ2 (6, N = 27) = 14.25, p = .027. Again the master’s degree cohort
appears to differ most from the other educational cohorts. Half of the respondents from
that group indicated they believed behavioral therapy is the least safe approach, and
another 41% chose panic focused psychodynamic psychotherapy. The bachelor’s degree
cohort unanimously chose emotion-focused psychotherapy for panic disorder as the least
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safe therapy approach, and answers from the doctorate level respondents were split
evenly among emotion-focused psychotherapy, panic focused psychodynamic
psychotherapy, and behavioral therapy approaches.
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Figure 53. Responses to the item regarding the least safe therapy approach for the
treatment of panic disorder.

For a survey item regarding the perceived safety and effectiveness of
antidepressant medications for panic disorder, there was also a significant finding of
difference among the educational level groups identified. The one-way analysis of
variance (ANOVA) comparing educational level with judged safety and effectiveness of
antidepressant medications for the treatment of panic disorder, showed significant
differences between groups, F(3,34 ), p = .013. A Tukey-Kramer post-hoc comparison of
the four groups showed that the bachelor’s degree cohort (M = 2.5) indicated significantly
less agreement with the survey item positing the safety and effectiveness of
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antidepressant medications for the treatment of panic disorder, than the associate’s,
master’s, and doctorate degree groups respectively (Ms = 1.5, 1.68 and 1.67). The result
of this first analysis appears in the Table 6 and Figure 14.

Table 6
Statistical Analysis of Responses to Item Regarding the Perceived Safety and
Effectiveness of Antidepressant Medications for Panic Disorder

Analysis of Variance Table

Between
Within
Total

Group
Associate
Bachelor
Master
Doctorate

Sum of
Squares
4.447
12.106
16.553

Count
6
4
22
6

Mean
Square
1.482
0.356

Df
3
34
37

F-Ratio
4.16
---------

Tukey-Kramer Multiple-Comparison Test
Mean
1.5
2.5
1.682
1.167
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Probability
Level
0.013
---------
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Figure 14. Educational Cohort responses for survey item stating antidepressants are safe
and effective for the treatment of panic disorder.

A one-way analysis of variance (ANOVA) also revealed a significant difference,
F(3,34), p = .02, among educational groups in their level of agreement with the statement:
“Medication alone is a safe and effective treatment for panic disorder.” The TukeyKramer post-hoc comparison indicated that the doctorate group (M = 2.33) indicated a
significantly higher level of agreement with this item than the master’s degree cohort (M
= 3.27). The difference between the bachelor (M = 3) and associate (M = 2.67) level
cohorts was not significant. The result of this analysis is presented in Table 7 and Figure
15.
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Table 7
Statistical Analysis of Responses to Item Stating: Medication Alone Is a Safe and
Effective Treatment for Panic Disorder

Analysis of Variance Table

Between
Within
Total

Group
Associate
Bachelor
Master
Doctorate

Sum of
Squares
4.967
15.030

Mean
Square
1.657
0.442

Df
3
34
37

F-Ratio
3.75
---------

Probability
Level
0.020
---------

Tukey-Kramer Multiple-Comparison Test
Count
Mean
Different from Groups
6
2.667
----4
3
----22
3.273
Doctorate
6
2.333
Master

Strongly Disagree 4.00

Somewhat Disagree 3.00

Somewhat Agree 2.00
Associate

Bachelor

Master

Doctorate

Figure 6. Educational cohort responses for survey item stating medication alone is a safe
and effective treatment for panic disorder.
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Regarding the statement: “I feel that I have the knowledge/training to effectively
help clients with panic disorder,” a one-way analysis of variance revealed another
significant difference among educational level groups, F(3,42), p = .024. The TukeyKramer’s post-hoc analysis of this item revealed that the doctorate and master’s level
groups (Ms = 1.5 and 1.82 respectively) indicated a significantly higher level of
agreement with the survey item, than bachelor’s and associate’s degree groups (Ms =
2.67 and 2 respectively).

Table 8
Statistical Analysis of Responses to the Item Stating: I feel that I have the
knowledge/training to effectively help clients with panic disorder

Analysis of Variance Table

Between
Within
Total

Group
Associate
Bachelor
Master
Doctorate

Sum of
Squares
4.712
18.940
23.652

Mean
Square
1.571
0.451

Df
3
42
45

F-Ratio
3.48
---------

Tukey-Kramer Multiple-Comparison Test
Count
Mean
6
2
6
2.667
28
1.821
6
1.5
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Probability
Level
0.240
---------

Different from Groups
----Master, Doctorate
Bachelor
Bachelor

Strongly Disagree 4.00

Somewhat Disagree 3.00

Somewhat Agree 2.00

Strongly Agree 1.00

Associate

Bachelor

Master

Doctorate

Figure 7. Responses to Item Stating “I feel that I have the knowledge/training to
effectively help clients with panic disorder.”

As seen in the Table 9 and Figure 17, one-way analysis (ANOVA) of the level of
agreement among educational level cohorts with another statement: “Our center needs to
revise its approach to treating panic disorder,” also demonstrated a significant level of
difference, F(3,41), p = .021. Post-hoc analysis (Tukey-Kramer’s Test) showed that the
bachelor’s degree group (M = 1.833) indicated a significantly greater level of agreement
with that statement than did the doctorate, master’s or associate’s degree cohorts, (Ms =
2.33, 2.74, 3.167).
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Table 9
Statistical Analysis of Responses to Item Stating: Our center needs to revise its approach
to treating panic disorder

Analysis of Variance Table

Between
Within
Total

Sum of
Squares
6.392
24.185
30.578

Group
Associate
Bachelor
Master
Doctorate

Mean
Square
2.131
0.590

Df
3
41
44

F-Ratio
3.61
---------

Probability
Level
0.021
---------

Tukey-Kramer Multiple-Comparison Test
Count
Mean
Different from Groups
6
3.167
Bachelor
6
1.833
Associate
27
2.741
----6
2.333
-----

Strongly Disagree 4.00

Somewhat Disagree 3.00

Somewhat Agree 2.00

Strongly Agree 1.00
Associate

Bachelor

Master

Doctorate

Figure 8. Responses for survey item stating, “Our center needs to revise its approach to
treating panic disorder.”
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There were no other significant differences found across the remaining items in
relation to discipline or educational level. Although one-way analysis of variance
(ANOVA) and goodness-of-fit tests (chi-squared) were also used to examine potential
differences related to extent of panic disorder specific training and age of participant,
there were no other significant findings for the survey data analyzed.
Phase Two Results: Database Review
The second phase of this study involved analyzing a 3-year sample of client
outcomes and duration data that was provided by the participating agency. Although the
parameters of this database review were narrowed to only include clients with “pure”
panic disorder (with or without agoraphobia) diagnoses, the agency was able to provide
figures on 138 records of applicable clients. The treatment conditions that were
identified in order to analyze the client outcome and duration were therapy only and
therapy with medication services. Of the panic disorder only cases, 19 received therapy
only, while 119 received a combination of medication and therapy. Since an admission
and termination date are requisite in order to calculate duration, and the participating
agency records GAF scores only at initial assessment and termination, only data from
clients who had terminated treatment during the three year sampling period could be used
for this analysis (n = 25). Although the sample was collected from a 3-year period, the
total number of clients that met the criteria of panic disorder only was very small.
Additionally, only five of the clients included in the sample were in the therapy only
treatment group, and 20 received therapy and benzodiazepine medication for the
treatment of panic disorder. These small subsample groups mean that this study has low
statistical power, and a type II error, or failure to detect differences when they exist, is
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more likely to occur (Cleophas, Zwinderman, Cleophas, Cleophas, & Cleophas-Allers,
2012). This limitation should be remembered when considering the results from the
database review analysis.
Outcomes. Client GAF scores for the two treatment groups. Admission GAF
scores ranged from 36 to 53 with a mean of 50.6, and termination scores had a range of
43 to 60 with a mean of 58.04. An independent-samples t-test was used to analyze for
difference in pre and post GAF scores for the two treatment groups described above. The
results of this analysis showed no significant difference in the scores for the therapy and
benzodiazepine medication (M = 7.55, SD = 2.31) and the therapy only (M = 7, SD =
1.87) treatment group conditions; t(23) = -0.492, p = .627. The result of this analysis is
presented in the Figure 18.

10.00

8.75

Change in
Pre and Post
Treatment
GAF scores

7.50

6.25

5.00
Therapy
Only

Therapy and
Medication

Figure 9. Comparison of change in GAF scores for therapy only and medication and
therapy treatment groups.
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Duration. The other variable from the client record database that was analyzed
for difference between treatment groups was duration. Treatment duration was measured
in months, and the 25 cases used for comparison ranged from 5 to 37 months with a mean
treatment period of 27.88 months. An independent-samples t-test was used to analyze for
difference in treatment duration between the therapy only and therapy and medication
treatment groups. The results of this analysis showed a highly significant difference in
the duration of treatment between groups t(23) = -2.518, p =.019. Specifically, the
therapy and medication group (M = 29.95, SD = 6.72) had a significantly longer
treatment duration, than the therapy only (M = 19.6, SD = 13.20) treatment condition.
This result is presented in Figure 19.

40.00

31.25

Treatment
Time in
Months

22.50

13.75

5.00
Therapy
Alone

Therapy and
Medication

Figure 19. Comparison of duration of treatment for therapy alone versus therapy and
medication groups.
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Discussion
This study of knowledge, skills, attitudes, and current practices within a large
community mental health agency was a case in point. The purpose was to examine the
potential options and dilemmas involved in implementing innovative or best practice
guidelines for the treatment of panic disorder. An accurate appraisal of current treatment
practices was accomplished through record review and data analysis. Additionally, a
computerized survey with Likert type scaled items along with some categorical items was
administered to key subgroups that influence client care in order to generate further data
about organizational members’ knowledge, skills, and attitudes regarding the treatment of
panic disorder. Those findings were also used to generate information regarding the
organization’s climate of change, readiness, and potential change process issues
(Bouckenooghe, Devos, & Van Den Broeck, 2009). Specifically, individual and systemic
perceptions of the potential need for innovative panic disorder treatment practices and
possible obstacles or impediments for implementing changes in treatment standards were
identified. The data generated from the record review and survey were reviewed in
relation to the three research questions that were formulated at the outset of this study
which included the following: a) To what extent are there differences in current
recommendations, reported practices, and reported knowledge or skills for the treatment
of panic disorder at the community mental health agency being studied? b) To what
extent are there differences between or within agency cohorts relative to their knowledge,
practices, and attitudes regarding the treatment of panic disorder? c) To what extent are
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treatment outcome variables related to the type of panic disorder treatment that clients
receive?
Phase One Discussion: Panic Disorder Treatment Survey
The panic disorder treatment survey was a computerized questionnaire about
knowledge, skills, attitudes, and practices that was given to direct client care and their
administrators at the participating agency. Survey responses were analyzed for themes of
overall agreement and between cohort differences. Several significant differences were
found between participant cohorts that were grouped according to demographic variables
including educational attainment and discipline. The discussion of this study’s findings
are presented below in reference to items regarding medication for the treatment of panic
disorder, therapy approaches, and general opinions items.
Medications. For items regarding the treatment of panic disorder with
medications there were several items on which most survey respondents agreed. For
example, the majority of participants indicated that they thought antidepressants (n=31,
81.1%) were the safest medication treatment option for treating panic disorder. The
participants confidence in the safety of antidepressants is in accord with research that
shows that antidepressants are clinically efficacious in reducing the number and severity
of reported panic attacks, while having the benefit of offering pharmacological coverage
for symptoms associated with mood disorder comorbidities and presenting limited
concerns about dependency or liability for abuse (American Psychiatric Association,
2009; Pollack, 2006). However, it should also be noted that research indicates that
antidepressants can result in several bothersome side effects (Physician’s Desk
Reference, 2007; Pollack, 2006). Additionally, since side effects are most likely to occur
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during the first few weeks of treatment, dosage is usually started at a lower rate and
gradually titrated up to the therapeutic level. These medications commonly take 6 to 8
weeks to reach effectiveness; thus, there may be a prolonged period before clients can
expect symptom reduction from antidepressants. If clients choose to discontinue
antidepressant treatments prematurely due to side effects or impatience, a discontinuation
syndrome and return of the panic attack is likely to result (American Psychiatric
Association, 2009; Shelton, 2006; Schatzberg, Blier, Delgado, Fava, Haddad, & Shelton,
2006). However, the biggest safety concern related to the use of antidepressants is
related to research that suggests they may lead to an increased risk for suicide and selfharm (Fergusson et al., 2005; Gunnell, Saperia, & Ashby, 2005). Ultimately, although
many factors must be considered such as potential presence of co-morbid mood disorder,
as well as the client’s tolerance for potential side effects and long-term commitment to
psychotropic intervention, antidepressants should not be consider a treatment option that
is free of risk (American Psychiatric Association, 2009).
In regards to benzodiazepines, most survey participants (n=33, 86.8%) rated it as
the least safe medication for treating panic disorder. Additionally, most respondents also
indicated agreement (strongly agree and somewhat agree response figures collapsed) that
benzodiazepines build dependency (n=42, 91.3%), that some clients may abuse or sell
their benzodiazepine prescription medications (n=43, 93.4%), and that clients prescribed
benzodiazepine medications for their panic disorder may not attend psychotherapy
appointments regularly” (n=35, 76.1%). Although providing a measurement of the
number of clients selling prescription benzodiazepines or missing therapy sessions was
outside of the scope of this study, the respondents’ level of agreement on these statements
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clarifies several perceived risks associated with benzodiazepines. Their concerns related
to substance dependency, decreased therapy attendance, and the potential for clients to
sell that medication also appeared to highlight a potential need for adjustments in agency
treatment guidelines related to prescribing benzodiazepines for panic disorder. For
example the agency may consider having clients start with psychotherapy services only
instead of starting with a combined therapy and pharmacological modality. Additionally,
if it is determined that a client might benefit from adjunctive pharmacological treatment,
practitioners should consider prescribing SSRIs or SNRIs as first line medications instead
of benzodiazepines as suggested by the American Psychiatric Association’s Panic
Disorder Treatment Guidelines (American Psychiatric Association, 2009).
Furthermore, concerns about the safety of benzodiazepines are supported by
research that shows individuals that are taking benzodiazepines are at an elevated risk for
motor vehicle accidents, and in the case of geriatric clients, falls and fractures (French, et
al., 2005; Kelly, Darke, & Ross, 2004; Landi, et al., 2005). These safety issues are likely
related to the commonly reported side effects of benzodiazepines, which include
sedation, fatigue, ataxia, slurred speech, memory impairment, and weakness (Physician’s
Desk Reference, 2007). Additionally, the use of benzodiazepines for more than 2 to 3
weeks results in physiologic dependence, and abrupt cessation of benzodiazepines can
lead to dangerous side effects including depression, suicidal behavior, psychosis,
seizures, and delirium tremens. Although a physician managed gradual taper is
recommended, clients often have great difficulty discontinuing benzodiazepine
medications due to withdrawal and rebound panic symptoms (Fava, Zielezny, Savron, &
Grandi, 1995; Klein, Colin, Stolk, & Lenox, 1994; Roy-Byrne, et al., 2003). In sum, the
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concerns of this study’s participants about the safety of prescribing benzodiazepines for
the treatment of panic disorder appear to be well founded.
Overall, more respondents chose antidepressants (n= 17, 45.9%) over
benzodiazepines (n=11, 29.7%) as the most effective medication for treating panic
disorder. However, ratings for safety for the two medications were not equally distributed
in the population when analyzed by discipline cohorts, and there was a significant (p =
.035) relationship between discipline and perceived safety of different classes of
medications. While most participants (87%) from the social worker, counseling, and
medical disciplines appeared to favor antidepressant medications in regards to safety,
over half (60%) of the participants from the psychologist group endorsed neither
medication as the safest approach for treating panic disorder. This finding suggests that,
unlike the other cohorts, the psychologists did not believe psychotropic medications are a
safe treatment intervention for panic disorder, and their preferences will be better
clarified by in the discussion of therapy approaches.
On a related item asking if participants agreed that antidepressants were safe and
effective for treating panic disorder, there were significant differences between discipline
(p=.048) and educational level groups (p=.013). Specifically, participants with an
associate, master, or doctorate degree, indicated more agreement with that item than
those with a bachelor’s degree, and the counseling and medical groups indicated a greater
degree of agreement than the psychologists. Psychologists also differed significantly (p.
= .008) from all other discipline cohorts in their greater level of agreement with the
statement, “benzodiazepine medications interfere with successful psychotherapy.”
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Therapies. Overall results of items that asked about different therapy treatment
approaches for panic disorder revealed a strong preference for cognitive behavioral
therapy among most participants. For example, when asked which therapy approach was
safest and which was most effective, the majority of participants chose cognitivebehavioral therapy, over behavioral therapy, panic focused psychodynamic
psychotherapy, and emotion-focused psychotherapy. Research supports the participants’
views that cognitive-behavioral therapy is a safe and effective treatment for panic
disorder; however, it also suggests that behavioral therapy and panic focused
psychodynamic psychotherapy are safe and effective treatment options as well. Most
respondents also indicated that cognitive-behavioral therapy was the most similar therapy
approach to their own, and the one with which they had the most training and experience.
Panic focused psychodynamic psychotherapy was the least familiar approach for most
survey participants, and more respondents also chose it as the least effective therapy
approach for treating panic disorder. Taken together, these findings seem to indicate that
the amount of knowledge, training, and experience that a clinician has is likely to affect
the perceived safety and effectiveness of that approach.
Upon further examination, when participant responses for the safest and most
effective therapy were analyzed by discipline there was a significant difference (p = .047)
found between cohorts. Specifically, the endorsements of participants from the medical
group were divided equally between panic focused psychodynamic psychotherapy and
cognitive behavioral therapy, while participants from the other discipline cohorts showed
a stronger preference for cognitive-behavioral therapy in regard to safety. When it is
considered that medical training models are more likely to ascribe to psychodynamic
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psychotherapy approaches, this finding appears to provide further support to the
previously stated interpretation that there is a relationship between training/familiarity
and perceived safety and effectiveness of a therapy approach.
Another highly significant difference (p = .005) among disciplines was found
regarding the statement: “When psychotherapy has been effective for patients with panic,
they will not tend to relapse.” The psychologist group, who likely has the most training
and familiarity with therapy, was significantly more likely to agree with this statement
than the medical and social work groups. Again, this finding appears to support a link
between familiarity and perceived efficacy. Additionally, it should be noted that research
suggests that although individuals with panic disorder are likely to experience recurring
cycles of symptom exacerbation, it is a very treatable and manageable mental health issue
(American Psychiatric Association, 2000; World Health Organization, 1998). Thus, there
may be some misconceptions about the nature of panic disorder among other disciplines,
and future agency trainings should address any knowledge gaps about the treatability of
panic disorder. This agency may also want to consider responding to the needs of clients
with panic disorder with an “episodes of care” approach as opposed to a continuous care
model, by predicting chances for symptom re-emergence and encouraging clients to
return for refresher sessions during periods of symptom exacerbation.
Regarding behavioral therapy that emphasizes exposure and desensitization, an
interesting difference was noted in the perceived safety and effectiveness of that approach
among the survey respondents. The vast majority (93. 4%) of participants indicated at
least some level of agreement with the statement: “behavioral therapy is a safe and
effective approach for treating panic disorder.” More specific items revealed that about
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23.3% of respondents ranked behavioral therapy as the most effective therapy approach;
however, behavioral therapy was also selected by more participants (46.2%) as the least
safe of therapy approaches. This appears to imply a perception that behavioral therapy
interventions including exposure and desensitization are effective, but not necessarily
safe. These findings are at odds with current literature on treating panic disorder that
indicates progress in managing panic attacks is actually attributable to exposure and
tolerance building, whether in a behavioral or cognitive behavioral model (Arch, Ayers,
Baker, Almklov, Dean, & Craske, 2013; Craske, & Vervliet, 2013). One possible
explanation for the concerns about safety expressed by participants in this study may be
due to their own discomfort with encouraging clients to participate in exposure
techniques that can be distressing initially. Although both therapists and clients may be
reluctant to engage in behavioral therapy interventions initially, there is no evidence of
that these practices are unsafe, and much evidence that it is ultimately highly beneficial in
building tolerance and decreasing panic.
Combination Treatments. The next section of survey response pertained to the
combination treatments versus therapy or medication alone for the treatment of panic
disorder. On these survey items most participants favored an antidepressant and therapy
combination for the treatment of panic disorder in regards to safety and effectiveness
(78.9% and 57.9% respectively). Additionally, the majority of respondents selected
medication alone as the least safe (63.2%) and least effective (60.5%) of the approaches
outlined. Although the participants of this study conveyed a common sentiment in their
marked preference for a combination of medication and therapy for the treatment of panic
disorder, research does not support an advantage to this approach. Studies have
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repeatedly demonstrated that cognitive-behavioral therapy alone has comparable efficacy
to cognitive-behavioral therapy with an antidepressant for the treatment of panic disorder
(Brown & Barlow, 1995; Barlow, Gorman, Shear, & Woods, 2000 ; Craske, Brown, &
Barlow, 1991; Fava, Zielezny, Savron, Grandi, 1995). Furthermore, it also suggests that
cognitive-behavioral therapy without adjunctive pharmacological treatment is most likely
to produce durable reduction in panic symptoms. Additionally, Milrod et al. (2007)
demonstrated promising preliminary findings with their use of panic-focused
psychodynamic psychotherapy.
The responses for least familiar and most familiar combination of treatments
differed significantly (p = .004 and p = .003 respectively) between disciplines. While the
other disciplines appeared to be most familiar with therapy and medication or all of the
combination treatments, the psychologists were most familiar with a therapy only
approach. Similarly, the medicine group indicated least familiarity with the therapy only
approach, while the psychology and counseling groups appeared to be the least familiar
with a medication only approach. The participants from the psychology group also
differed significantly (p = .017) from the other discipline groups by indicating a stronger
level of agreement with an item stating that therapy alone is a safe and effective treatment
approach for panic disorder.
The differences among disciplines outlined above may just be another example of
how individuals will tend to look more favorably on innovations with which they have
the most exposure and experience (Rogers, 2003). Psychologist are likely to have the
most experience and training in therapy, while the medical group (psychiatrists and
nurses) are more likely to have the most experience in working with clients who receive
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medications for their symptoms. This difference in job responsibilities may also allow
psychologists to see more gains from therapy due to their primary role as therapy
providers. Furthermore, the literature appears to support the notions that therapy alone
can produce comparable initial results and superior long-term results in the treatment of
panic disorder (Otto, Smits, & Reese 2006).
General Opinions. The general opinion items on the survey indicated that the
majority of participants felt well-trained and competent t in their panic disorder treatment
practices. For example, the majority of participants surveyed indicated that they had
received training in treating panic disorder through readings (71.1%), coursework
(62.2%), and supervision (51.1%). Additionally, most also felt they had enough
knowledge and training about panic disorder treatment (84.7%) and thought their own
and the agency’s treatment practices were safe and effective (93.2% and 93.3%
respectively). It should be noted that a limitation to the survey method used assess the
participants’ knowledge base was that it involved self-report, and not an actual test of
competency for panic disorder treatment strategies. Therefore, there is a possibility that
the respondents may have felt a desire to present favorably or believed that they were
better informed than they actually were. Thus, this finding should be interpreted with
those potential sources of bias in mind.
However, many participants also indicated areas of training and treatment
practices that might benefit from improvement. For example, participants with an
associate or bachelor’s degree were significantly less likely to indicate that they felt they
had the knowledge and training that they needed to help clients with panic disorder (p =
.024), than those from higher educational attainment cohorts. This finding suggests there
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might be an opportunity for more expert clinicians within the organization to share their
knowledge about panic disorder treatments with those who are expressing further training
needs. Participants with a bachelor degree were also significantly (p = .021) more likely
to agree with the item stating: “Our center needs to revise its approach to treating panic
disorder.” Specifically, one potential change in treatment guidelines that garnered
support from the majority of overall respondents (78.3%) was that the agency should
refer clients with panic disorder for psychotherapy prior to considering them for referral
for medication.
Phase Two Discussion: Database Review
The second phase of this study consisted of analyzing 3 years of client data in
order to gain insight into the agency’s current treatment practices and related client
outcomes. Despite current clinical practice guidelines that recommend antidepressants be
used as the first-line medication for the treatment of panic disorder, of the 138 clients
identified as having pure panic disorder, 119 were receiving a combination of
benzodiazepines and therapy services (American Psychiatric Association, 2009). This
incongruence in treatment guidelines and actual practices was consistent with a
longitudinal study that suggested most patients treated for panic disorder were still
receiving benzodiazepines (Bruce, Vasile, & Goisman, 2003).
As previously mentioned, the necessity of an admission and termination date in
order to calculate duration of treatment and differences in pre and post treatment GAF
scores, led to a small sample size (n=25). Of these participants, five included in the
sample were in the therapy only treatment group, and 20 received therapy and
benzodiazepine medication for the treatment of panic disorder. The small subsample
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groups in this study decreases its statistical power, and a type II error, or failure to detect
differences when they exist, may be more likely to occur (Cleophas,Zwinderman,
Cleophas, Cleophas, & Cleophas-Allers, 2012). This limitation should be kept in mind
when considering the discussion below that explores differences and similarities between
treatment groups related to outcome variables including outcome scores and treatment
duration.
Outcomes. The mean difference in pre and post GAF scores for the therapy only
and the combination therapy and benzodiazepine medication treatment groups were very
similar (Ms = 7 and 7.5 respectively), and statistical analysis (independent t-test) revealed
no significant (p = .627) difference between the two groups on this outcome variable.
This is consistent with research showing that therapy alone is comparable to therapy with
medication for treating panic disorder (Barlow, Gorman, Shear, & Woods, 2000;
Schmidt, & Smith, 2005; Westra, Stewart, & Conrad, 2002). Since there is no apparent
benefit to adding benzodiazepine medication to therapy when treating panic disorder, the
participating agency should consider whether combination treatment is merited for most
panic disorder only cases considering the added costs and safety risks that come with
prescribing medications.
A limitation to this study is the lack of measurement for maintenance of progress
after treatment has ceased. It would be interesting to see if there were any differences in
the durability of treatment gains at a 1-year follow up. Previous researches have
suggested that the concurrent use of benzodiazepines with therapy can decrease longterm treatment gains and maintenance (Barlow, Gorman, Shear, & Woods, 2000; Brown
& Barlow, 1995; Craske, Brown, & Barlow, 1991; Craske, & Vervliet, 2013; Fava, et al.,
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1995; Westra, et al., 2004). Differences in treatment durability have been attributed to
interference of benzodiazepines with the consolidation of learned psychoeducational
material and rebound panic symptoms in the cases of clients who cease medication.
Since these and other factors may affect long-term maintenance of treatment progress the
participating agency may want to consider using a follow up outcome measure for clients
periodically after termination.
Duration. The next outcome variable that was analyzed for differences between
the combination therapy and benzodiazepine medication versus the therapy only
treatment group was duration of treatment in months. There was a significant (p = .019)
difference between groups on this variable, and the combination group clients were in
treatment many more months than the therapy only group on average (Ms=29.95 and
19.6 respectively). This difference suggests that benzodiazepine medication may be
slowing clients’ progress. This finding could be related to previously mentioned research
that indicates that benzodiazepine medication interferes with recall of psychoeducational
material that is helpful in decreasing symptoms of panic disorder (Westra, et al., 2004).
It may also suggest that benzodiazepines interfere with psychotherapy by decreasing
symptoms during in vivo experiences of anxiety and panic, thus decreasing the client’s
ability to build tolerance for these symptoms through unfiltered exposure.
Additionally, it may be that clients attribute progress to the benzodiazepine
medication, thus missing potential opportunities to build self-efficacy in managing their
panic disorder and reach therapeutic goals.
A limitation for this study is the lack of related treatment information from which
to draw inferences about this significant difference in treatment duration. For example,
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factors such as number of sessions, type of therapy provided, or patient demographic
variables may also co-vary with the treatment modality to affect duration. Additionally,
this agency only had initial and termination GAF scores for clients who had already
terminated treatment. Therefore, both groups of clients may be making the same amount
of progress in the same amount of time, but those in the combination group may be
continuing treatment longer for other reasons such as continued medication prescriptions
or to support a disability claim. Future researchers may want to design studies that have
more points of measurement for outcome than just pre and post treatment and condition
specific inventories such as a Beck Anxiety Inventory (BAI; Beck, & Steer, 1993) or
Panic Disorder Severity Scale (PDSS; Shear et al., 1997; Shear & Maser, 1994) in order
to clarify the nature of potential treatment duration differences. Additionally, the
participating agency may wish to increase frequency of assessing treatment outcomes and
share information with clients about progress in order to foster efficiency for the agency
and feelings of self-efficacy and hope for clients. In addition to a GAF score, which may
have limited utility and poor inter-rater reliability, they should consider utilizing an
outcome measure that can provide more information on treatment progress such as the
Outcome Questionnaire-45 (OQ-45; Lambert et al., 2004) or the Brief Symptoms
Inventory (BSI; Derogatis, 1993)
Overall, the results of the survey and database review for this study were
consistent with many of the potential issues identified at the outset of this project. For
example, survey participants voiced concerns about safety and dependency issues related
to benzodiazepine prescription for panic disorder. Additionally, the respondents indicated
concerns about therapy attendance rates for clients receiving those medications, and they
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appeared to favor a shift in agency referral practices that would have clients enroll in
therapy services prior to consideration for treatment with medication. These findings
suggest an identified problem at the participating agency, and client care personnel are
likely to be receptive to information about innovative practices to address these dilemmas
(Rogers, 2003). As Schulz and Greenberg (1995) suggested, the key groups at this
agency including discipline and educational level cohorts had somewhat different
perceptions of current practices and possible innovations in regard to potential benefits
and consequences. Thus, it will be important to encourage adoption of change within
these groups in a manner that suits the unique perspectives they revealed in their survey
responses. Due to the different interests and opinions expressed between groups, it will
be especially important to identify innovation champions within each subgroup (Rogers
2003:2004). Innovation champions are charismatic individuals that can address the
resistance among their peers and increase the likelihood of success of a proposed
innovation. Due to their attractive interpersonal styles they are also key individuals
through which to disseminate knowledge and information about the various innovative
treatment options that might be beneficial for this agency. Further specific
recommendations for this agency and other like it will be discussed in the concluding
section about clinical implications.
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Clinical Implications
This study is a case in point of one agency’s knowledge, skills, attitudes, and
practices regarding the treatment of panic disorder. Specifically, it showed that although
differences in beliefs about the effectiveness and safety of treatments were often seen
among providers from different disciplines, differences in client outcomes due to
treatment practices where minimal. It provided support for the existing literature base on
panic disorder, and raised further concerns about the potential drawbacks of adjunctive
psychotropic interventions for panic disorder, including the possibility of prolonged
treatment duration. It is a translational research piece that adds to the existing literature
on panic disorder treatment by presenting findings from a multidisciplinary community
mental health setting. From its inception, it was intended that the findings from this
study be both useful for the participating agency and generalizable to other organizations
hoping to implement best practice standards for treating panic disorder.
The theme of comfort and confidence in the treatment practices which were most
familiar presents an opportunity for consciousness raising work within the participating
agency (Prockaska & Diclemente, 1984). The goals of this consciousness raising should
be to increase self-efficacy in applying innovative panic disorder treatment practices, as
well as shifting the decisional balance by increasing perceived positive outcomes for
learning and applying those strategies (Bandura, 1977; Janis and Mann, 1977).
Consciousness raising strategies can promote motivation and persistence for change, and
safeguard against resistance or relapse (Levesque, Prochaska, & Prochaska, 1999). One
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example of how this strategy could be applied at the participating agency would include
offering information about the current research and treatment standards that are not
currently being met. Additionally, the client care employees would also likely benefit
from hearing more about the variety of empirically validated treatment strategies that are
available for treating panic disorder such as cognitive behavioral therapy, exposure-based
behavioral therapy, and panic focused psychodynamic psychotherapy.
The review of professional practice standards and agency treatment regarding
psychotropic interventions for the treatment of panic disorder should address the two
specific problems identified: (a) The number of benzodiazepine prescriptions for panic
disorder appears to be inconsistent with current professional treatment standards, and
clinicians should consider ways of helping clients taper off those medications. Some may
benefit from a different medication if mood issues are present, and others may benefit
from gaining better control of symptoms and increased tolerance through therapeutic
change. (b) The process for referral in the participating agency should help clients and
clinicians capture opportunities for therapeutic change prior to adding a medication.
Specifically, clients should be given the opportunity to benefit from therapy before being
referred for medication. By applying a least invasive intervention approach, risks,
expenses, and potential side effects can be avoided for many clients who would receive
comparable treatment benefits from therapy alone.
It appears that the survey participants already have some awareness of the
agency’s current needs with regard to adopting more innovative panic disorder treatment
strategies, and Roger’s (2003; 2004) work on diffusion of innovations suggests that they
can be assisted in working through the first stage of diffusion by the change agents within
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their organization. If change agents such as team leaders can help others increase
knowledge and exposure to other therapeutic strategies, they may make them more
comfortable with adopting those new strategies and recruit more stakeholders in
promoting change. Specifically, this agency and others like it should consider offering
training opportunities such as in-services, sponsored convention attendance, or
continuing education courses regarding a variety of effective treatment approaches such
as cognitive-behavioral therapy, panic focused psychodynamic psychotherapy, and
behavioral therapy. A few influential team members could be given “advanced training
in treating panic disorder.” When the advantages of their newly learned skills are shared
with others at the agency, others will be more likely to consider adopting innovative
treatment strategies and become future stakeholders in this change process.
This dissertation was a translational research piece that was developed to compare
professional treatment standards with actual practices at a large metropolitan community
mental health agency. It was designed in hopes of clarifying potential obstacles and
dilemmas in implementing innovative and best practice treatment standards in a real
world setting. A database review confirmed high rates of benzodiazepine prescriptions
for clients with panic disorder. Analysis revealed that, consistent with previous research,
clients receiving a combination of benzodiazepines and therapy did not have improved
outcomes. Furthermore, the results of this study showed a trend of prolonged treatment
duration for clients prescribed benzodiazepines for panic disorder. A survey also
provided insight into the current knowledge, skills and attitudes of client care personnel
at the participating agency regarding panic disorder treatment. The results of this survey
indicated that clinicians have identified problems with agency treatment practices related
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to the prescription of benzodiazepines for panic disorder treatment, and they would likely
be open to receiving more information about potential innovative solutions to those
issues. Survey results also showed there is an opportunity to increase the knowledge base
within this agency regarding the variety of efficacious therapy approaches for treating
panic disorder. Specifically, due to the findings of this current study and review of
literature regarding the treatment of panic disorder, emphasis on the effectiveness and
durability of therapy only approaches should be emphasized in applying these results to
the participating agency and other like.
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